Хроническая сердечная недостаточность. Клинические рекомендации 2024

Галявич А. С.; Терещенко С. Н.; Ускач Т. М.; Агеев Ф. Т.; Аронов Д. М.; Арутюнов Г. П.; Беграмбекова Ю. Л.; Беленков Ю. Н.; Бойцов С. А.; Бубнова М. Г.; Васюк Ю. А.; Виллевальде С. В.; Виноградова Н. Г.; Гарганеева A. А.; Гендлин Г. Е.; Гиляревский С. Р.; Глезер М. Г.; Готье С. В.; Гринштейн Ю. И.; Довженко Т. В.; Драпкина О. М.; Дупляков Д. В.; Жиров И. В.; Затейщиков Д. А.; Звартау Н. Э.; Иртюга О. Б.; Кобалава Ж. Д.; Козиолова Н. А.; Коротеев А. В.; Либис Р. А.; Лопатин Ю. М.; Мареев В. Ю.; Мареев Ю. В.; Мацкеплишвили С. Т.; Михайлов Е. Н.; Насонова С. Н.; Нарусов О. Ю.; Недогода С. В.; Недошивин А. О.; Овчинников А. Г.; Орлова Я. А.; Перепеч Н. Б.; Погосова Н. В.; Римская Е. М.; Самко А. Н.; Саидова М. А.; Сапельников О. В.; Сафиуллина А. А.; Ситникова М. Ю.; Скворцов А. А.; Скибицкий В. В.; Стукалова О. В.; Тарловская Е. И.; Терещенко А. С.; Чесникова А. И.; Федотов П. А.; Фомин И. В.; Хасанов Н. Р.; Шевченко А. О.; Шапошник И. И.; Шария М. А.; Шляхто Е. В.; Явелов И. С.; Якушин С. С.

Статья

Хроническая сердечная недостаточность. Клинические рекомендации 2024

Галявич А. С., Терещенко С. Н., Ускач Т. М., Агеев Ф. Т., Аронов Д. М., Арутюнов Г. П., Беграмбекова Ю. Л., Беленков Ю. Н., Бойцов С. А., Бубнова М. Г., Васюк Ю. А., Виллевальде С. В., Виноградова Н. Г., Гарганеева A. А., Гендлин Г. Е., Гиляревский С. Р., Глезер М. Г., Готье С. В., Гринштейн Ю. И., Довженко Т. В., Драпкина О. М., Дупляков Д. В., Жиров И. В., Затейщиков Д. А., Звартау Н. Э., Иртюга О. Б., Кобалава Ж. Д., Козиолова Н. А., Коротеев А. В., Либис Р. А., Лопатин Ю. М., Мареев В. Ю., Мареев Ю. В., Мацкеплишвили С. Т., Михайлов Е. Н., Насонова С. Н., Нарусов О. Ю., Недогода С. В., Недошивин А. О., Овчинников А. Г., Орлова Я. А., Перепеч Н. Б., Погосова Н. В., Римская Е. М., Самко А. Н., Саидова М. А., Сапельников О. В., Сафиуллина А. А., Ситникова М. Ю., Скворцов А. А., Скибицкий В. В., Стукалова О. В., Тарловская Е. И., Терещенко А. С., Чесникова А. И., Федотов П. А., Фомин И. В., Хасанов Н. Р., Шевченко А. О., Шапошник И. И., Шария М. А., Шляхто Е. В., Явелов И. С., Якушин С. С.

2024

https://doi.org/10.15829/1560-4071-2024-6162

Российское кардиологическое общество (РКО)При участии: Национального общества по изучению сердечной недостаточности и заболеваний миокарда (НОИСН), Общества специалистов по сердечной недостаточности (ОССН), Российского научного медицинского общества терапевтов (РНМОТ)Одобрено Научно-практическим Советом Минздрава Российской Федерации (12.09.2024)

Цитирование

Список литературы

1. Фомин И. В. Артериальная гипертония в Российской Федерации — последние 10 лет. Что дальше? Сердце. 2007;6(3):1-6.

2. Ситникова М. Ю., Юрченко А. В., Лясникова Е. А., и др. Результаты Российского госпитального регистра хронической сердечной недостаточности в 3 субъектах Российской Федерации. Кардиология. 2015;55(10):5-13. doi:10.18565/cardio.2015.10.5-13.

3. Поляков Д. С., Фомин И. В., Беленков Ю. Н. и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА -ХСН. Кардиология. 2021;61(4):4-14. doi:10.18087/cardio.2021.4.n1628.

4. Терещенко С. Н., Алаева Е. Н., Нарусов О. Ю. и др. Распространенность и диагностика дилатационной кардиомиопатии по данным Российского регистра. Кардиология. 2012;(7):67-72.

5. Cleland JG, Swedberg K, Follath F, et al.; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme — a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003 Mar;24(5):442-63. doi:10.1016/s0195-668x(02)00823-0.

6. Heidenreich PA, Albert NM, Allen LA, et al.; American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606-19. doi:10.1161/HHF.0b013e318291329a.

7. Steinberg BA, Zhao X, Heidenreich PA, et al.; Get With the Guidelines Scientific Advisory Committee and Investigators. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126(1):65-75. doi:10.1161/CIRCULATIONAHA.111.080770.

8. Lam CSP, Voors AA, Piotr P, et al. Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction. Eur Heart J. 2020;41(25):2353-5. doi:10.1093/eurheartj/ehaa158.

9. Lund LH, Claggett B, Liu J, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018;20(8):1230-9. doi:10.1002/ejhf.1149.

10. Solomon SD, McMurray JJV, Anand IS, et al.; PARAGON-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381(17):1609-20. doi:10.1056/NEJMoa1908655.

11. Lam CS, Solomon SD. The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%). Eur J Heart Fail. 2014;16(10):1049-55. doi:10.1002/ejhf.159.

12. Агеев Ф. Т., Овчинников А. Г. Диастолическая сердечная недостаточность: 20 лет спустя. Актуальные вопросы патогенеза, диагностики и лечения сердечной недостаточности с сохраненной ФВЛЖ. Кардиология. 2023;63(3):3-12. doi:10.18087/cardio.2023.3.n2376.

13. Терещенко С. Н., Жиров И. В., Нарусов О. Ю. и др. Диагностика и лечение хронической и острой сердечной недостаточности. Кардиологический вестник. 2016;2:3-33.

14. McMurray JJ. Clinical practice. Systolic heart failure. N Engl J Med. 2010;362(3):228-38. doi:10.1056/NEJMcp0909392.

15. Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA. 2011;306(15):1669-78. doi:10.1001/jama.2011.1474.

16. Dunlay SM, Redfield MM, Weston SA, et al. Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol. 2009 Oct 27;54(18):1695-702. doi:10.1016/j.jacc.2009.08.019.

17. Koh AS, Tay WT, Teng THK, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2017;19(12):1624-34. doi:10.1002/ejhf.945.

18. Vedin O, Lam CSP, Koh AS, et al. Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study. Circ Heart Fail. 2017;10(6):e003875. doi:10.1161/CIRCHEARTFAILURE.117.003875.

19. Kapoor JR, Kapoor R, Ju C, et al. Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. JACC Heart Fail. 2016;4(6):464-72. doi:10.1016/j.jchf.2016.02.017.

20. Dhingra A, Garg A, Kaur S, et al. Epidemiology of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2014;11(4):354-65. doi:10.1007/s11897-014-0223-7.

21. Liu M, Fang F, Yu CM. Noncardiac comorbidities in heart failure with preserved ejection fraction — commonly ignored fact. Circ J. 2015;79(5):954-9. doi:10.1253/circj.CJ-15-0056.

22. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14(10):591-602. doi:10.1038/nrcardio.2017.65.

23. Xanthakis V, Enserro DM, Larson MG, et al. Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages in the Community. JACC Heart Fail. 2016;4(10):808-15. doi:10.1016/j.jchf.2016.05.001.

24. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004;43(3):317-27. doi:10.1016/j.jacc.2003.07.046.

25. Senni M, Gavazzi A, Oliva F, et al.; IN HF Outcome Investigators. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. Int J Cardiol. 2014;173(2):163-9. doi:10.1016/j.ijcard.2014.02.018.

26. Cowie MR, Fox KF, Wood DA, et al. Hospitalization of patients with heart failure: a population-based study. Eur Heart J. 2002;23(11):877-85. doi:10.1053/euhj.2001.2973.

27. McAlister FA, Teo KK, Taher M, et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J. 1999;138(1 Pt 1):87-94. doi:10.1016/s0002-8703(99)70251-6.

28. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-71. doi:10.1016/j.jacc.2013.02.092.

29. Redfield MM. Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2017;376(9):897. doi:10.1056/NEJMc1615918.

30. Paulus WJ, Dal Canto E. Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction. JACC Heart Fail. 2018;6(1):1-7. doi:10.1016/j.jchf.2017.07.012.

31. Wehner GJ, Jing L, Haggerty CM, et al. Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie? Eur Heart J. 2020;41(12):1249-57. doi:10.1093/eurheartj/ehz550.

32. Stewart S, Playford D, Scalia GM, et al.; NEDA Investigators. Ejection fraction and mortality: a nationwide register-based cohort study of 499153 women and men. Eur J Heart Fail. 2021;23(3):406-16. doi:10.1002/ejhf.2047.

33. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27(1):65-75. doi:10.1093/eurheartj/ehi555.

34. Komajda M, Carson PE, Hetzel S, et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail. 2011;4(1):27-35. doi:10.1161/CIRCHEARTFAILURE.109.932996.

35. Ketchum ES, Levy WC. Establishing prognosis in heart failure: a multimarker approach. Prog Cardiovasc Dis. 2011;54(2):86-96. doi:10.1016/j.pcad.2011.03.003.

36. Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88(1):107-15. doi:10.1161/01.cir.88.1.107.

37. Фомин И. В. Хрониченская сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016;(8):7-13. doi:10.15829/1560-4071-2016-8-7-13.

38. Мареев В. Ю., Даниелян М. О., Беленков Ю. Н. Влияние терапии на прогноз и выживаемость больных с хронической сердечной недостаточностью. Русский медицинкий журнал. 1999;2:9.

39. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation. 2009;119(24):3070-7. doi:10.1161/CIRCULATIONAHA.108.815944.

40. Wedel H, McMurray JJ, Lindberg M, et al.; CORONA Study Group. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail. 2009;11(3):281-91. doi:10.1093/eurjhf/hfn046.

41. Ощепкова Е. В., Лазарева Н. В., Сатлыкова Д. Ф., Терещенко С. Н. Первые результаты Российского регистра хронической сердечной недостаточности. Кардиология. 2015;55(5):22-8.

42. Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23(3):352-80. doi:10.1002/ejhf.2115.

43. Wilcox JE, Fang JC, Margulies KB, Mann DL. Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel. J Am Coll Cardiol. 2020;76(6):719-34. doi:10.1016/j.jacc.2020.05.075.

44. Шляхто Е. В. Классификация сердечной недостаточности: фокус на профилактику. Российский кардиологический журнал. 2023;28(1):5351. doi:10.15829/1560-4071-2023-5351. EDN: RVHDCY

45. Галявич А. С., Недогода С. В., Арутюнов Г. П., Беленков Ю. Н. О классификации хронической сердечной недостаточности. Российский кардиологический журнал. 2023;28(9):5584. doi:10.15829/1560-4071-2023-5584. EDN: ZGXELX

46. Иртюга О. Б., Недогода С. В., Ситникова М. Ю. и др. Результаты опроса Российского кардиологического общества "Хроническая сердечная недостаточность. Нерешенные проблемы". Российский кардиологический журнал. 2024;29(6):5944. doi:10.15829/1560-4071-2024-5944. EDN: KXYUXW

47. Davie AP, Francis CM, Caruana L, et al. Assessing diagnosis in heart failure: which features are any use? QJM. 1997;90(5):335-9. doi:10.1093/qjmed/90.5.335.

48. Mant J, Doust J, Roalfe A, et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess. 2009;13(32):1-207, iii. doi:10.3310/hta13320.

49. Oudejans I, Mosterd A, Bloemen JA, et al. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. Eur J Heart Fail. 2011;13(5):518-27. doi:10.1093/eurjhf/hfr021.

50. Fonseca C. Diagnosis of heart failure in primary care. Heart Fail Rev. 2006;11(2):95-107. doi:10.1007/s10741-006-9481-0.

51. Kelder JC, Cramer MJ, van Wijngaarden J, et al. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011;124(25):2865-73. doi:10.1161/CIRCULATIONAHA.111.019216.

52. Weingärtner O, Hasan T, Böhm M. Pathophysiologie und Differentialdiagnose der Dyspnoe [Pathophysiology and differential diagnosis of dyspnea]. Herz. 2004;29(6):595-601. German. doi:10.1007/s00059-004-2594-0.

53. Fries R. Ursachensuche bei generalisierten und lokalisierten Odemen [Differential diagnosis of leg edema]. MMW Fortschr Med. 2004;146(16):39-41. German.

54. Thibodeau JT, Turer AT, Gualano SK, et al. Characterization of a novel symptom of advanced heart failure: bendopnea. JACC Heart Fail. 2014;2(1):24-31. doi:10.1016/j.jchf.2013.07.009.

55. Roberts E, Ludman AJ, Dworzynski K, et al.; NICE Guideline Development Group for Acute Heart Failure. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015;350:h910. doi:10.1136/bmj.h910.

56. Zaphiriou A, Robb S, Murray-Thomas T, et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail. 2005;7(4):537-41. doi:10.1016/j.ejheart.2005.01.022.

57. Fuat A, Murphy JJ, Hungin AP, et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract. 2006;56(526):327-33.

58. Yamamoto K, Burnett JC Jr, Bermudez EA, et al. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail. 2000;6(3):194-200. doi:10.1054/jcaf.2000.9676.

59. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350(9088):1349-53. doi:10.1016/S0140-6736(97)06031-5.

60. Krishnaswamy P, Lubien E, Clopton P, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med. 2001;111(4):274-9. doi:10.1016/s0002-9343(01)00841-5.

61. Kelder JC, Cramer MJ, Verweij WM, et al. Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure. J Card Fail. 2011;17(9):729-34. doi:10.1016/j.cardfail.2011.04.013.

62. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37(2):386-91. doi:10.1016/s0735-1097(00)01157-8.

63. McCullough PA, Duc P, Omland T, et al.; Breathing Not Properly Multinational Study Investigators. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41(3):571-9. doi:10.1053/ajkd.2003.50118.

64. Jankowska EA, Malyszko J, Ardehali H, et al. Iron status in patients with chronic heart failure. Eur Heart J. 2013;34(11):827-34. doi:10.1093/eurheartj/ehs377.

65. McDonagh T, Damy T, Doehner W, et al. Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. Eur J Heart Fail. 2018;20(12):1664-72. doi:10.1002/ejhf.1305.

66. Anker SD, Kirwan BA, van Veldhuisen DJ, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. 2018;20(1):125-33. doi:10.1002/ejhf.823.

67. Jankowska EA, von Haehling S, Anker SD, et al. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J. 2013;34(11):816-29. doi:10.1093/eurheartj/ehs224.

68. Damman K, Valente MA, Voors AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35(7):455-69. doi:10.1093/eurheartj/eht386.

69. Filippatos G, Farmakis D, Parissis J. Renal dysfunction and heart failure: things are seldom what they seem. Eur Heart J. 2014;35(7):416-8. doi:10.1093/eurheartj/eht515.

70. Desai AS. Hyperkalemia in patients with heart failure: incidence, prevalence, and management. Curr Heart Fail Rep. 2009;6(4):272-80. doi:10.1007/s11897-009-0037-1.

71. Ewid M, Sherif H, Allihimy AS, et al. AST/ALT ratio predicts the functional severity of chronic heart failure with reduced left ventricular ejection fraction. BMC Res Notes. 2020;13(1):178. doi:10.1186/s13104-020-05031-3.

72. Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003;42(11):1933-40. doi:10.1016/j.jacc.2003.07.016.

73. Bonilla-Palomas JL, Gámez-López AL, Moreno-Conde M, et al. Hypoalbuminemia in acute heart failure patients: causes and its impact on hospital and long-term mortality. J Card Fail. 2014;20(5):350-8. doi:10.1016/j.cardfail.2014.01.016.

74. Aguilar D, Bozkurt B, Ramasubbu K, Deswal A. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol. 2009;54(5):422-8. doi:10.1016/j.jacc.2009.04.049.

75. Passino C, Pingitore A, Landi P, et al. Prognostic value of combined measurement of brain natriuretic peptide and triiodothyronine in heart failure. J Card Fail. 2009;15(1):35-40. doi:10.1016/j.cardfail.2008.08.008.

76. Matsushita K, Coresh J, Sang Y, et al.; CKD Prognosis Consortium. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514-25. doi:10.1016/S2213-8587(15)00040-6.

77. Khunti K, Squire I, Abrams KR, Sutton AJ. Accuracy of a 12-lead electrocardiogram in screening patients with suspected heart failure for open access echocardiography: a systematic review and meta-analysis. Eur J Heart Fail. 2004;6(5):571-6. doi:10.1016/j.ejheart.2004.03.013.

78. Davie AP, Francis CM, Love MP, et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ. 1996;312(7025):222. doi:10.1136/bmj.312.7025.222.

79. Thomas JT, Kelly RF, Thomas SJ, et al. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. Am J Med. 2002;112(6):437-45. doi:10.1016/s0002-9343(02)01048-3.

80. Spinarová L. Zmĕny v EKG u chronického srdecního selhání a po transplantaci [Changes in the ECG in chronic heart failure and after transplantation]. Vnitr Lek. 2003;49(9):730-3. Czech.

81. Baldasseroni S, Gentile A, Gorini M, et al.; Italian Network on Congestive Heart Failure Investigators. Intraventricular conduction defects in patients with congestive heart failure: left but not right bundle branch block is an independent predictor of prognosis. A report from the Italian Network on Congestive Heart Failure (IN-CHF database). Ital Heart J. 2003;4(9):607-13.

82. Tribouilloy C, Rusinaru D, Mahjoub H, et al. Impact of echocardiography in patients hospitalized for heart failure: a prospective observational study. Arch Cardiovasc Dis. 2008;101(7-8):465-73. doi:10.1016/j.acvd.2008.06.012.

83. Kirkpatrick JN, Vannan MA, Narula J, Lang RM. Echocardiography in heart failure: applications, utility, and new horizons. J Am Coll Cardiol. 2007;50(5):381-96. doi:10.1016/j.jacc.2007.03.048.

84. Senni M, Rodeheffer RJ, Tribouilloy CM, et al. Use of echocardiography in the management of congestive heart failure in the community. J Am Coll Cardiol. 1999;33(1):164-70. doi:10.1016/s0735-1097(98)00523-3.

85. Agha SA, Kalogeropoulos AP, Shih J, et al. Echocardiography and risk prediction in advanced heart failure: incremental value over clinical markers. J Card Fail. 2009;15(7):586-92. doi:10.1016/j.cardfail.2009.03.002.

86. Chambers JB, Garbi M, Nieman K, et al. Appropriateness criteria for the use of cardiovascular imaging in heart valve disease in adults: a European Association of Cardiovascular Imaging report of literature review and current practice. Eur Heart J Cardiovasc Imaging. 2017;18(5):489-98. doi:10.1093/ehjci/jew309.

87. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911-39. doi:10.1016/j.echo.2014.07.012.

88. Echocardiographic Normal Ranges Meta-Analysis of the Left Heart Collaboration. Ethnic-Specific Normative Reference Values for Echocardiographic LA and LV Size, LV Mass, and Systolic Function: The EchoNoRMAL Study. JACC Cardiovasc Imaging. 2015;8(6):656-65. doi:10.1016/j.jcmg.2015.02.014.

89. Muraru D, Badano LP, Peluso D, et al. Comprehensive analysis of left ventricular geometry and function by three-dimensional echocardiography in healthy adults. J Am Soc Echocardiogr. 2013;26(6):618-28. doi:10.1016/j.echo.2013.03.014.

90. Caballero L, Kou S, Dulgheru R, et al. Echocardiographic reference ranges for normal cardiac Doppler data: results from the NORRE Study. Eur Heart J Cardiovasc Imaging. 2015;16(9):1031-41. doi:10.1093/ehjci/jev083.

91. Dorosz JL, Lezotte DC, Weitzenkamp DA, et al. Performance of 3-dimensional echocardiography in measuring left ventricular volumes and ejection fraction: a systematic review and meta-analysis. J Am Coll Cardiol. 2012;59(20):1799-808. doi:10.1016/j.jacc.2012.01.037.

92. Goldenberg I, Moss AJ, Hall WJ, et al.; MADIT-CRT Executive Committee. Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011;124(14):1527-36. doi:10.1161/CIRCULATIONAHA.110.014324.

93. Thavendiranathan P, Liu S, Datta S, et al. Automated quantification of mitral inflow and aortic outflow stroke volumes by three-dimensional real-time volume color-flow Doppler transthoracic echocardiography: comparison with pulsed-wave Doppler and cardiac magnetic resonance imaging. J Am Soc Echocardiogr. 2012;25(1):56-65. doi:10.1016/j.echo.2011.10.004.

94. Alherbish A, Becher H, Alemayehu W, et al.; Alberta HEART investigators. Impact of contrast echocardiography on accurate discrimination of specific degree of left ventricular systolic dysfunction and comparison with cardiac magnetic resonance imaging. Echocardiography. 2018;35(11):1746-54. doi:10.1111/echo.14152.

95. Hoffmann R, von Bardeleben S, ten Cate F, et al. Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiography. Eur Heart J. 2005;26(6):607-16. doi:10.1093/eurheartj/ehi083.

96. Hoffmann R, Barletta G, von Bardeleben S, et al. Analysis of left ventricular volumes and function: a multicenter comparison of cardiac magnetic resonance imaging, cine ventriculography, and unenhanced and contrast-enhanced two-dimensional and three-dimensional echocardiography. J Am Soc Echocardiogr. 2014;27(3):292-301. doi:10.1016/j.echo.2013.12.005.

97. Thavendiranathan P, Poulin F, Lim KD, et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014;63(25 Pt A):2751-68. doi:10.1016/j.jacc.2014.01.073.

98. Mignot A, Donal E, Zaroui A, et al. Global longitudinal strain as a major predictor of cardiac events in patients with depressed left ventricular function: a multicenter study. J Am Soc Echocardiogr. 2010;23(10):1019-24. doi:10.1016/j.echo.2010.07.019.

99. Yingchoncharoen T, Agarwal S, Popović ZB, Marwick TH. Normal ranges of left ventricular strain: a meta-analysis. J Am Soc Echocardiogr. 2013;26(2):185-91. doi:10.1016/j.echo.2012.10.008.

100. Stanton T, Leano R, Marwick TH. Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. Circ Cardiovasc Imaging. 2009;2(5):356-64. doi:10.1161/CIRCIMAGING.109.862334.

101. Bansal M, Cho GY, Chan J, et al. Feasibility and accuracy of different techniques of two-dimensional speckle based strain and validation with harmonic phase magnetic resonance imaging. J Am Soc Echocardiogr. 2008;21(12):1318-25. doi:10.1016/j.echo.2008.09.021.

102. Potter E, Marwick TH. Assessment of Left Ventricular Function by Echocardiography: The Case for Routinely Adding Global Longitudinal Strain to Ejection Fraction. JACC Cardiovasc Imaging. 2018;11(2 Pt 1):260-74. doi:10.1016/j.jcmg.2017.11.017.

103. Morris DA, Ma XX, Belyavskiy E, et al. Left ventricular longitudinal systolic function analysed by 2D speckle-tracking echocardiography in heart failure with preserved ejection fraction: a meta-analysis. Open Heart. 2017;4(2):e000630. doi:10.1136/openhrt-2017-000630.

104. Shah AM, Claggett B, Sweitzer NK, et al. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Circulation. 2015;132(5):402-14. doi:10.1161/CIRCULATIONAHA.115.015884.

105. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233-70. doi:10.1093/ehjci/jev014. Erratum in: Eur Heart J Cardiovasc Imaging. 2016;17(4):412. doi:10.1093/ehjci/jew041. Erratum in: Eur Heart J Cardiovasc Imaging. 2016;17(9):969. doi:10.1093/ehjci/jew124.

106. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277-314. doi:10.1016/j.echo.2016.01.011.

107. Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40(40):3297-317. doi:10.1093/eurheartj/ehz641. Erratum in: Eur Heart J. 2021;42(13):1274. doi:10.1093/eurheartj/ehaa1016.

108. Reddy YNV, Carter RE, Obokata M, et al. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018;138(9):861-70. doi:10.1161/CIRCULATIONAHA.118.034646.

109. Lancellotti P, Galderisi M, Edvardsen T, et al. Echo-Doppler estimation of left ventricular filling pressure: results of the multicentre EACVI Euro-Filling study. Eur Heart J Cardiovasc Imaging. 2017;18(9):961-8. doi:10.1093/ehjci/jex067.

110. Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020;22(3):391-412. doi:10.1002/ejhf.1741.

111. Sepehrvand N, Alemayehu W, Dyck GJB, et al. External Validation of the H2F-PEF Model in Diagnosing Patients With Heart Failure and Preserved Ejection Fraction. Circulation. 2019;139(20):2377-9. doi:10.1161/CIRCULATIONAHA.118.038594.

112. Barandiarán Aizpurua A, Sanders-van Wijk S, Brunner-La Rocca HP, et al. Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction. Eur J Heart Fail. 2020;22(3):413-21. doi:10.1002/ejhf.1614.

113. Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11(2):130-9. doi:10.1093/eurjhf/hfn013.

114. Jolicœur EM, Dunning A, Castelvecchio S, et al. Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction: insights from STICH. J Am Coll Cardiol. 2015;66(19):2092-100. doi:10.1016/j.jacc.2015.08.882.

115. Tonino PA, De Bruyne B, Pijls NH, et al.; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360(3):213-24. doi:10.1056/NEJMoa0807611.

116. Toth G, De Bruyne B, Casselman F, et al. Fractional flow reserve-guided versus angiography-guided coronary artery bypass graft surgery. Circulation. 2013;128(13):1405-11. doi:10.1161/CIRCULATIONAHA.113.002740.

117. Velazquez EJ, Lee KL, Deja MA, et al.; STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364(17):1607-16. doi:10.1056/NEJMoa1100356.

118. Beller GA, Heede RC. SPECT imaging for detecting coronary artery disease and determining prognosis by noninvasive assessment of myocardial perfusion and myocardial viability. J Cardiovasc Transl Res. 2011;4(4):416-24. doi:10.1007/s12265-011-9290-2.

119. Beanlands RS, Nichol G, Huszti E, et al.; PARR-2 Investigators. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50(20):2002-12. doi:10.1016/j.jacc.2007.09.006.

120. González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585-94. doi:10.1093/eurheartj/ehv338.

121. Longhi S, Guidalotti PL, Quarta CC, et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. JACC Cardiovasc Imaging. 2014;7(5):531-2. doi:10.1016/j.jcmg.2014.03.004.

122. Bokhari S, Castaño A, Pozniakoff T, et al. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195-201. doi:10.1161/CIRCIMAGING.112.000132.

123. Aljaroudi WA, Desai MY, Tang WH, et al. Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques. J Nucl Cardiol. 2014;21(2):271-83. doi:10.1007/s12350-013-9800-5.

124. Saric M, Armour AC, Arnaout MS, et al. Guidelines for the Use of Echocardiography in the Evaluation of a Cardiac Source of Embolism. J Am Soc Echocardiogr. 2016;29(1):1-42. doi:10.1016/j.echo.2015.09.011.

125. Khemka A, Sawada SG. Dobutamine echocardiography for assessment of viability in the current era. Curr Opin Cardiol. 2019;34(5):484-9. doi:10.1097/HCO.0000000000000658.

126. Ling LF, Marwick TH, Flores DR, et al. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging. 2013;6(3):363-72. doi:10.1161/CIRCIMAGING.112.000138.

127. Bonow RO, Maurer G, Lee KL, et al.; STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364(17):1617-25. doi:10.1056/NEJMoa1100358.

128. deFilippi CR, Willett DL, Brickner ME, et al. Usefulness of dobutamine echocardiography in distinguishing severe from nonsevere valvular aortic stenosis in patients with depressed left ventricular function and low transvalvular gradients. Am J Cardiol. 1995;75(2):191-4. doi:10.1016/s0002-9149(00)80078-8.

129. Tribouilloy C, Lévy F, Rusinaru D, et al. Outcome after aortic valve replacement for low-flow/low-gradient aortic stenosis without contractile reserve on dobutamine stress echocardiography. J Am Coll Cardiol. 2009;53(20):1865-73. doi:10.1016/j.jacc.2009.02.026.

130. Clavel MA, Fuchs C, Burwash IG, et al. Predictors of outcomes in low-flow, low-gradient aortic stenosis: results of the multicenter TOPAS Study. Circulation. 2008;118(14 Suppl):S234-42. doi:10.1161/CIRCULATIONAHA.107.757427.

131. Garnier F, Eicher JC, Jazayeri S, et al. Usefulness and limitations of contractile reserve evaluation in patients with low-flow, low-gradient aortic stenosis eligible for cardiac resynchronization therapy. Eur J Heart Fail. 2014;16(6):648-54. doi:10.1002/ejhf.78.

132. Овчинников А. Г., Агеев Ф. Т., Алёхин М. Н. и др. Диастолическая трансторакальная стресс-эхокардиография с дозированной физической нагрузкой в диагностике сердечной недостаточности с сохраненной фракцией выброса: показания, методология, интерпретация результатов. Согласованное мнение экспертов, выработанное под эгидой ФГБУ "Национальный медицинский исследовательский центр кардиологии" МЗ РФ, Общества специалистов по сердечной недостаточности (ОССН) и Российской ассоциации специалистов ультразвуковой диагностики в медицине (РАСУДМ). Кардиология. 020;60(12):48-63. doi:10.18087/cardio.2020.12.n1219.

133. Erdei T, Smiseth OA, Marino P, Fraser AG. A systematic review of diastolic stress tests in heart failure with preserved ejection fraction, with proposals from the EU-FP7 MEDIA study group. Eur J Heart Fail. 2014;16(12):1345-61. doi:10.1002/ejhf.184.

134. Donal E, Lund LH, Oger E, et al.; KaRen investigators. Value of exercise echocardiography in heart failure with preserved ejection fraction: a substudy from the KaRen study. Eur Heart J Cardiovasc Imaging. 2016;17(1):106-13. doi:10.1093/ehjci/jev144.

135. Nagueh SF, Chang SM, Nabi F, et al. Cardiac Imaging in Patients With Heart Failure and Preserved Ejection Fraction. Circ Cardiovasc Imaging. 2017;10(9):e006547. doi:10.1161/CIRCIMAGING.117.006547.

136. ten Kate GJ, Caliskan K, Dedic A, et al. Computed tomography coronary imaging as a gatekeeper for invasive coronary angiography in patients with newly diagnosed heart failure of unknown aetiology. Eur J Heart Fail. 2013;15(9):1028-34. doi:10.1093/eurjhf/hft090.

137. Sousa PA, Bettencourt N, Dias Ferreira N, et al. Role of cardiac multidetector computed tomography in the exclusion of ischemic etiology in heart failure patients. Rev Port Cardiol. 2014;33(10):629-36. English, Portuguese. doi:10.1016/j.repc.2014.02.028.

138. Chow BJW, Coyle D, Hossain A, et al.; IMAGE-HF Investigators. Computed tomography coronary angiography for patients with heart failure (CTA-HF): a randomized controlled trial (IMAGE-HF 1C). Eur Heart J Cardiovasc Imaging. 2021;22(9):1083-90. doi:10.1093/ehjci/jeaa109.

139. Cademartiri F, Casolo G, Clemente A, et al. Coronary CT angiography: a guide to examination, interpretation, and clinical indications. Expert Rev Cardiovasc Ther. 2021;19(5):413-25. doi:10.1080/14779072.2021.1915132.

140. Carrabba N, Berteotti M, Taborchi G, et al. Integration of CTA in the Diagnostic Workup of New Onset Chest Pain in Clinical Practice. Biomed Res Int. 2019;2019:2647079. doi:10.1155/2019/2647079.

141. Kramer CM, Barkhausen J, Bucciarelli-Ducci C, et al. Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. J Cardiovasc Magn Reson. 2020;22(1):17. doi:10.1186/s12968-020-00607-1.

142. Iles LM, Ellims AH, Llewellyn H, et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. Eur Heart J Cardiovasc Imaging. 2015;16(1):14-22. doi:10.1093/ehjci/jeu182.

143. Gulati A, Jabbour A, Ismail TF, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309(9):896-908. doi:10.1001/jama.2013.1363. Erratum in: JAMA. 2013;310(1):99.

144. Puntmann VO, Carr-White G, Jabbour A, et al.; International T1 Multicentre CMR Outcome Study. T1-Mapping and Outcome in Nonischemic Cardiomyopathy: All-Cause Mortality and Heart Failure. JACC Cardiovasc Imaging. 2016;9(1):40-50. doi:10.1016/j.jcmg.2015.12.001. Erratum in: JACC Cardiovasc Imaging. 2017;10(3):384. doi:10.1016/j.jcmg.2017.01.006.

145. Weidman EK, Dean KE, Rivera W, et al. MRI safety: a report of current practice and advancements in patient preparation and screening. Clin Imaging. 2015;39(6):935-7. doi:10.1016/j.clinimag.2015.09.002.

146. Tsai LL, Grant AK, Mortele KJ, et al. A Practical Guide to MR Imaging Safety: What Radiologists Need to Know. Radiographics. 2015;35(6):1722-37. doi:10.1148/rg.2015150108.

147. Sechtem U, Pflugfelder P, Higgins CB. Quantification of cardiac function by conventional and cine magnetic resonance imaging. Cardiovasc Intervent Radiol. 1987;10(6):365-73. doi:10.1007/BF02577347.

148. Pattynama PM, Lamb HJ, van der Velde EA, et al. Left ventricular measurements with cine and spin-echo MR imaging: a study of reproducibility with variance component analysis. Radiology. 1993;187(1):261-8. doi:10.1148/radiology.187.1.8451425.

149. Reichek N. Magnetic resonance imaging for assessment of myocardial function. Magn Reson Q. 1991;7(4):255-74.

150. Hudsmith LE, Petersen SE, Francis JM, et al. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson. 2005;7(5):775-82. doi:10.1080/10976640500295516.

151. Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2006;8(3):417-26. doi:10.1080/10976640600572889.

152. Contaldi C, Capuano F, Romano L, et al. Cardiovascular Magnetic Resonance in Right Heart and Pulmonary Circulation Disorders. Heart Fail Clin. 2021;17(1):57-75. doi:10.1016/j.hfc.2020.08.006.

153. Pons-Lladó G, Carreras F, Borrás X, et al. Comparison of morphologic assessment of hypertrophic cardiomyopathy by magnetic resonance versus echocardiographic imaging. Am J Cardiol. 1997;79(12):1651-6. doi:10.1016/s0002-9149(97)00216-6.

154. Moon JC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart. 2004;90(6):645-9. doi:10.1136/hrt.2003.014969.

155. Fattori R, Biagini E, Lorenzini M, et al. Significance of magnetic resonance imaging in apical hypertrophic cardiomyopathy. Am J Cardiol. 2010;105(11):1592-6. doi:10.1016/j.amjcard.2010.01.020.

156. Ashrith G, Gupta D, Hanmer J, Weiss RM. Cardiovascular magnetic resonance characterization of left ventricular non-compaction provides independent prognostic information in patients with incident heart failure or suspected cardiomyopathy. J Cardiovasc Magn Reson. 2014;16(1):64. doi:10.1186/s12968-014-0064-2.

157. Choi Y, Kim SM, Lee SC, et al. Quantification of left ventricular trabeculae using cardiovascular magnetic resonance for the diagnosis of left ventricular non-compaction: evaluation of trabecular volume and refined semi-quantitative criteria. J Cardiovasc Magn Reson. 2016;18(1):24. doi:10.1186/s12968-016-0245-2.

158. Mavrogeni SI, Markousis-Mavrogenis G, Vartela V, et al. The pivotal role of cardiovascular imaging in the identification and risk stratification of non-compaction cardiomyopathy patients. Heart Fail Rev. 2020;25(6):1007-15. doi:10.1007/s10741-019-09898-8.

159. Patel AR, Kramer CM. Role of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Nonischemic Cardiomyopathy. JACC Cardiovasc Imaging. 2017;10(10 Pt A):1180-93. doi:10.1016/j.jcmg.2017.08.005.

160. Trivieri MG, Spagnolo P, Birnie D, et al. Challenges in Cardiac and Pulmonary Sarcoidosis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;76(16):1878-901. doi:10.1016/j.jacc.2020.08.042.

161. Hundley WG, Bluemke DA, Bogaert J, et al. Society for Cardiovascular Magnetic Resonance (SCMR) guidelines for reporting cardiovascular magnetic resonance examinations. J Cardiovasc Magn Reson. 2022;24(1):29. doi:10.1186/s12968-021-00827-z.

162. Contaldi C, Dellegrottaglie S, Mauro C, et al. Role of Cardiac Magnetic Resonance Imaging in Heart Failure. Heart Fail Clin. 2021;17(2):207-21. doi:10.1016/j.hfc.2021.01.001.

163. Gonzalez JA, Kramer CM. Role of Imaging Techniques for Diagnosis, Prognosis and Management of Heart Failure Patients: Cardiac Magnetic Resonance. Curr Heart Fail Rep. 2015;12(4):276-83. doi:10.1007/s11897-015-0261-9.

164. Yoshida A, Ishibashi-Ueda H, Yamada N, et al. Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure. Eur J Heart Fail. 2013;15(2):166-75. doi:10.1093/eurjhf/hfs206.

165. Abbasi SA, Ertel A, Shah RV, et al. Impact of cardiovascular magnetic resonance on management and clinical decision-making in heart failure patients. J Cardiovasc Magn Reson. 2013;15(1):89. doi:10.1186/1532-429X-15-89. Erratum in: J Cardiovasc Magn Reson. 2014;16:20.

166. Lurz P, Eitel I, Adam J, et al. Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis. JACC Cardiovasc Imaging. 2012;5(5):513-24. doi:10.1016/j.jcmg.2011.11.022.

167. Sobol I, Horn EM, Dele-Michael A, et al. 123 Assessment of Unexplained Cardiomyopathy (CMP) — Clinical Utility of Delayed-Enhancement Cardiac Magnetic Resonance (DE-CMR) Compared to Endomyocardial Biopsy. J. Hear. Lung Transplant. 2012;31(4): S50. doi:10.1016/j.healun.2012.01.127.

168. Karamitsos TD, Papanastasiou CA. Cardiac Magnetic Resonance T1 Mapping for Cardiac Amyloidosis: The Best Way Forward. JACC Cardiovasc Imaging. 2020;13(1 Pt 1):81-2. doi:10.1016/j.jcmg.2019.04.011.

169. Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol. 2008;51(10):1022-30. doi:10.1016/j.jacc.2007.10.049.

170. Nam BD, Kim SM, Jung HN, et al. Comparison of quantitative imaging parameters using cardiovascular magnetic resonance between cardiac amyloidosis and hypertrophic cardiomyopathy: inversion time scout versus T1 mapping. Int J Cardiovasc Imaging. 2018;34(11):1769-77. doi:10.1007/s10554-018-1385-2.

171. Fontana M, Pica S, Reant P, et al. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2015;132(16):1570-9. doi:10.1161/CIRCULATIONAHA.115.016567.

172. Karur GR, Robison S, Iwanochko RM, et al. Use of Myocardial T1 Mapping at 3.0 T to Differentiate Anderson-Fabry Disease from Hypertrophic Cardiomyopathy. Radiology. 2018;288(2):398-406. doi:10.1148/radiol.2018172613.

173. Sado DM, White SK, Piechnik SK, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6(3):392-8. doi:10.1161/CIRCIMAGING.112.000070.

174. Vega-Adauy J, Tok OO, Celik A, et al. Comprehensive Assessment of Heart Failure with Preserved Ejection Fraction Using Cardiac MRI. Heart Fail Clin. 2021;17(3):447-62. doi:10.1016/j.hfc.2021.03.006.

175. Sinigiani G, De Michieli L, Pauro A, et al. Atypical Late Gadolinium Enhancement in Patients with Cardiac Amyloidosis: Clinical Correlates and Prognostic Value. Journal of Cardiovascular Magnetic Resonance. 2024;26(Suppl. 1):100443. doi:10.1016/j.jocmr.2024.100443

176. Aherne E, Chow K, Carr J. Cardiac T1 mapping: Techniques and applications. J Magn Reson Imaging. 2020;51(5):1336-56. doi:10.1002/jmri.26866.

177. Ponsiglione A, Gambardella M, Green R, et al. Cardiovascular magnetic resonance native T1 mapping in Anderson-Fabry disease: a systematic review and meta-analysis. J Cardiovasc Magn Reson. 2022;24(1):31. doi:10.1186/s12968-022-00859-z.

178. Zhang J, Li Y, Xu Q, et al.Cardiac Magnetic Resonance Imaging for Diagnosis of Cardiac Sarcoidosis: A Meta-Analysis. Can Respir J. 2018;2018:7457369. doi:10.1155/2018/7457369.

179. Bing R, Dweck MR. Myocardial fibrosis: why image, how to image and clinical implications. Heart. 2019;105(23):1832-40. doi:10.1136/heartjnl-2019-315560.

180. Robinson AA, Chow K, Salerno M. Myocardial T1 and ECV Measurement: Underlying Concepts and Technical Considerations. JACC Cardiovasc Imaging. 2019;12(11 Pt 2):2332-44. doi:10.1016/j.jcmg.2019.06.031.

181. Moon JC, Messroghli DR, Kellman P, et al.; Society for Cardiovascular Magnetic Resonance Imaging; Cardiovascular Magnetic Resonance Working Group of the European Society of Cardiology. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15(1):92. doi:10.1186/1532-429X-15-92.

182. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100(19): 1992-2002. doi:10.1161/01.cir.100.19.1992.

183. Mrsic Z, Mousavi N, Hulten E, Bittencourt MS. The Prognostic Value of Late Gadolinium Enhancement in Nonischemic Heart Disease. Magn Reson Imaging Clin N Am. 2019;27(3):545-61. doi:10.1016/j.mric.2019.04.010.

184. Hamirani YS, Wong A, Kramer CM, Salerno M. Effect of microvascular obstruction and intramyocardial hemorrhage by CMR on LV remodeling and outcomes after myocardial infarction: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2014;7(9):940-52. doi:10.1016/j.jcmg.2014.06.012.

185. Daoulah A, Alsheikh-Ali AA, Al-Faifi SM, et al. Cardiac resynchronization therapy in patients with postero-lateral scar by cardiac magnetic resonance: A systematic review and meta-analysis. J Electrocardiol. 2015;48(5):783-90. doi:10.1016/j.jelectrocard.2015.06.012.

186. Acosta J, Fernández-Armenta J, Borràs R, et al. Scar Characterization to Predict Life-Threatening Arrhythmic Events and Sudden Cardiac Death in Patients With Cardiac Resynchronization Therapy: The GAUDI-CRT Study. JACC Cardiovasc Imaging. 2018;11(4):561-72. doi:10.1016/j.jcmg.2017.04.021.

187. Nguyên UC, Mafi-Rad M, Aben JP, et al. A novel approach for left ventricular lead placement in cardiac resynchronization therapy: Intraprocedural integration of coronary venous electroanatomic mapping with delayed enhancement cardiac magnetic resonance imaging. Heart Rhythm. 2017;14(1):110-9. doi:10.1016/j.hrthm.2016.09.015.

188. Kočková R, Sedláček K, Wichterle D, et al. Cardiac resynchronization therapy guided by cardiac magnetic resonance imaging: A prospective, single-centre randomized study (CMR-CRT). Int J Cardiol. 2018;270:325-30. doi:10.1016/j.ijcard.2018.06.009.

189. Demirel F, Adiyaman A, Timmer JR, et al. Myocardial scar characteristics based on cardiac magnetic resonance imaging is associated with ventricular tachyarrhythmia in patients with ischemic cardiomyopathy. Int J Cardiol. 2014;177(2):392-9. doi:10.1016/j.ijcard.2014.08.132.

190. Scott PA, Rosengarten JA, Curzen NP, Morgan JM. Late gadolinium enhancement cardiac magnetic resonance imaging for the prediction of ventricular tachyarrhythmic events: a meta-analysis. Eur J Heart Fail. 2013;15(9):1019-27. doi:10.1093/eurjhf/hft053.

191. Bartolome SD, Torres F. Severe pulmonary arterial hypertension: stratification of medical therapies, mechanical support, and lung transplantation. Heart Fail Rev. 2016;21(3):347-56. doi:10.1007/s10741-016-9562-7.

192. Kaemmerer H, Apitz C, Brockmeier K, et al. Pulmonary hypertension in adults with congenital heart disease: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272S:79-88. doi:10.1016/j.ijcard.2018.08.078.

193. Adamson PB, Abraham WT, Bourge RC, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7(6):935-44. doi:10.1161/CIRCHEARTFAILURE.113.001229.

194. Prasad A, Hastings JL, Shibata S, et al. Characterization of static and dynamic left ventricular diastolic function in patients with heart failure with a preserved ejection fraction. Circ Heart Fail. 2010;3(5):617-26. doi:10.1161/CIRCHEARTFAILURE.109.867044.

195. Vachiéry JL, Tedford RJ, Rosenkranz S, et al. Pulmonary hypertension due to left heart disease. Eur Respir J. 2019;53(1):1801897. doi:10.1183/13993003.01897-2018.

196. Fletcher GF, Ades PA, Kligfield P, et al.; American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology, Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation. 2013;128(8):873-934. doi:10.1161/CIR.0b013e31829b5b44.

197. Corrà U, Piepoli MF, Adamopoulos S, et al. Cardiopulmonary exercise testing in systolic heart failure in 2014: the evolving prognostic role: a position paper from the committee on exercise physiology and training of the heart failure association of the ESC. Eur J Heart Fail. 2014;16(9):929-41. doi:10.1002/ejhf.156.

198. Piepoli MF, Conraads V, Corrà U, et al. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail. 2011;13(4):347-57. doi:10.1093/eurjhf/hfr017.

199. Corrà U, Agostoni PG, Anker SD, et al. Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(1):3-15. doi:10.1002/ejhf.979. Erratum in: Eur J Heart Fail. 2018;20(10):1501. doi:10.1002/ejhf.1186.

200. Cooper LT, Baughman KL, Feldman AM, et al.; American Heart Association; American College of Cardiology; European Society of Cardiology; Heart Failure Society of America; Heart Failure Association of the European Society of Cardiology. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol. 2007;50(19):1914-31. doi:10.1016/j.jacc.2007.09.008.

201. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis — natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med. 1997;336(26):1860-6. doi:10.1056/NEJM199706263362603.

202. SOLVD Investigators; Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302. doi:10.1056/NEJM199108013250501.

203. Velazquez EJ, Morrow DA, DeVore AD, et al.; PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019;380(6):539-48. doi:10.1056/NEJMoa1812851. Erratum in: N Engl J Med. 2019;380(11):1090. doi:10.1056/NEJMx190009.

204. Pfeffer MA, McMurray JJ, Velazquez EJ, et al.; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893-906. doi:10.1056/NEJMoa032292. Erratum in: N Engl J Med. 2004;350(2):203.

205. Maggioni AP, Anand I, Gottlieb SO, L et al.; Val-HeFT Investigators (Valsartan Heart Failure Trial). Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2002;40(8):1414-21. doi:10.1016/s0735-1097(02)02304-5.

206. Dimopoulos K, Salukhe TV, Coats AJ, et al. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker). Int J Cardiol. 2004;93(2-3):105-11. doi:10.1016/j.ijcard.2003.10.001.

207. McMurray JJV, Solomon SD, Inzucchi SE, et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303.

208. Packer M, Anker SD, Butler J, et al.; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-24. doi:10.1056/NEJMoa2022190.

209. Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-29. doi:10.1016/S0140-6736(20)31824-9.

210. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349-55. doi:10.1056/NEJM199605233342101.

211. Gattis WA, O’Connor CM, Leimberger JD, et al. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol. 2003;91(2):169-74. doi:10.1016/s0002-9149(02)03104-1.

212. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13.

213. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-17. doi:10.1056/NEJM199909023411001.

214. McMurray JJ, Packer M, Desai AS, et al.; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077.

215. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429-35. doi:10.1056/NEJM198706043162301.

216. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273(18):1450-6. Erratum in: JAMA 1995;274(6):462.

217. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100(23):2312-8. doi:10.1161/01.cir.100.23.2312.

218. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669-77. doi:10.1056/NEJM199209033271001.

219. SOLVD Investigators; Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327(10):685-91. doi:10.1056/NEJM199209033271003. Erratum in: N Engl J Med 1992;327(24):1768.

220. Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333(25):1670-6. doi:10.1056/NEJM199512213332503.

221. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342(8875):821-8.

222. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283(10):1295-302. doi:10.1001/jama.283.10.1295.

223. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385-90. doi:10.1016/s0140-6736(00)04560-8.

224. Jondeau G, Neuder Y, Eicher JC, et al.; B-CONVINCED Investigators. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J. 2009;30(18):2186-92. doi:10.1093/eurheartj/ehp323.

225. Zannad F, McMurray JJ, Krum H, et al.; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21. doi:10.1056/NEJMoa1009492.

226. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543-51. doi:10.1056/NEJMoa040135.

227. Faris R, Flather M, Purcell H, et al. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol. 2002;82(2): 149-58. doi:10.1016/s0167-5273(01)00600-3.

228. Dormans TP, van Meyel JJ, Gerlag PG, et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996;28(2):376-82. doi:10.1016/0735-1097(96)00161-1.

229. Vargo DL, Kramer WG, Black PK, et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995;57(6):601-9. doi:10.1016/0009-9236(95)90222-8.

230. Patterson JH, Adams KF Jr, Applefeld MM, et al. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy. 1994;14(5):514-21.

231. Cosín J, Díez J; TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4(4):507-13. doi:10.1016/s1388-9842(02)00122-8. Erratum in: Eur J Heart Fail 2002;4(5):667.

232. Yamato M, Sasaki T, Honda K, et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J. 2003;67(5):384-90. doi:10.1253/circj.67.384. Erratum in: Circ J. 2003;67(7):649. Erratum in: Circ J. 2003;67(6):565.

233. Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;151(5):985-91. doi:10.1016/j.ahj.2005.06.036. Erratum in: Am Heart J. 2006;152(2):354.

234. Granger CB, McMurray JJ, Yusuf S, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772-6. doi:10.1016/S0140-6736(03)14284-5.

235. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667-75. doi:10.1056/NEJMoa010713.

236. Swedberg K, Komajda M, Böhm M, et al.; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875-85. doi:10.1016/S0140-6736(10)61198-1. Erratum in: Lancet. 2010;376(9757):1988.

237. Böhm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013;102(1):11-22. doi:10.1007/s00392-012-0467-8.

238. Swedberg K, Komajda M, Böhm M, et al.; SHIFT Investigators. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol. 2012;59(22):1938-45. doi:10.1016/j.jacc.2012.01.020.

239. Fox K, Ford I, Steg PG, et al.; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807-16. doi:10.1016/S0140-6736(08)61170-8.

240. Hobbs RE. Digoxin’s effect on mortality and hospitalization in heart failure: implications of the DIG study. Digitalis Investigation Group. Cleve Clin J Med. 1997;64(5):234-7. doi:10.3949/ccjm.64.5.234.

241. Gheorghiade M, Fonarow GC, van Veldhuisen DJ, et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013;34(20):1489-97. doi:10.1093/eurheartj/eht120.

242. Jorge E, Baptista R, Martins H, et al. Digoxin in advanced heart failure patients: a question of rhythm. Rev Port Cardiol. 2013;32(4):303-10. doi:10.1016/j.repc.2012.11.007.

243. Gheorghiade M, Patel K, Filippatos G, et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. 2013;15(5):551-9. doi:10.1093/eurjhf/hft010.

244. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289(7):871-8. doi:10.1001/jama.289.7.871.

245. Adams KF Jr, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46(3):497-504. doi:10.1016/j.jacc.2005.02.091.

246. Malik A, Masson R, Singh S, et al. Digoxin Discontinuation and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019;74(5):617-27. doi:10.1016/j.jacc.2019.05.064.

247. Homma S, Thompson JL, Pullicino PM, et al.; WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366(20):1859-69. doi:10.1056/NEJMoa1202299.

248. Zannad F, Anker SD, Byra WM, et al.; COMMANDER HF Investigators. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. N Engl J Med. 2018;379(14):1332-42. doi:10.1056/NEJMoa1808848.

249. Sulaica EM, Macaulay TE, Helbing RR, et al. A comparison of anticoagulation, antiplatelet, and placebo treatment for patients with heart failure reduced ejection fraction in sinus rhythm: a systematic review and meta-analysis. Heart Fail Rev. 2020;25(2):207-16. doi:10.1007/s10741-019-09818-w.

250. Gheorghiade M, Böhm M, Greene SJ, et al.; ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013;309(11):1125-35. doi:10.1001/jama.2013.1954. Erratum in: JAMA. 2013;309(14):1461.

251. Parving HH, Brenner BM, McMurray JJ, et al.; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204-13. doi:10.1056/NEJMoa1208799.

252. Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010;31(7):824-31. doi:10.1093/eurheartj/ehp604.

253. Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011;11(2):115-28. doi:10.2165/11587580-000000000-00000.

254. Erdmann E, Charbonnel B, Wilcox RG, et al.; PROactive Investigators. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007;30(11):2773-8. doi:10.2337/dc07-0717.

255. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991;83(1):52-60. doi:10.1161/01.cir.83.1.52.

256. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997;96(3):856-63. doi:10.1161/01.cir.96.3.856.

257. Thackray S, Witte K, Clark AL, Cleland JG. Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail. 2000;2(2):209-12. doi:10.1016/s1388-9842(00)00080-5.

258. Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996;335(15):1107-14. doi:10.1056/NEJM199610103351504.

259. Huerta C, Varas-Lorenzo C, Castellsague J, García Rodríguez LA. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart. 2006;92(11):1610-5. doi:10.1136/hrt.2005.082388.

260. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324(12):781-8. doi:10.1056/NEJM199103213241201.

261. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321(6):406-12. doi:10.1056/NEJM198908103210629.

262. Kotecha D, Holmes J, Krum H, et al.; Beta-Blockers in Heart Failure Collaborative Group. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384(9961):2235-43. doi:10.1016/S0140-6736(14)61373-8.

263. Cleland JG, Massie BM, Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Fail. 1999;1(1):41-5. doi:10.1016/S1388-9842(99)00009-4.

264. Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36(30):1990-7. doi:10.1093/eurheartj/ehv186.

265. Cleland JG, Calvert M, Freemantle N, et al. The Heart Failure Revascularisation Trial (HEART). Eur J Heart Fail. 2011;13(2):227-33. doi:10.1093/eurjhf/hfq230.

266. Panza JA, Holly TA, Asch FM, et al. Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol. 2013;61(18):1860-70. doi:10.1016/j.jacc.2013.02.014.

267. Mondésert B, Khairy P, Schram G, et al. Impact of revascularization in patients with sustained ventricular arrhythmias, prior myocardial infarction, and preserved left ventricular ejection fraction. Heart Rhythm. 2016;13(6):1221-7. doi:10.1016/j.hrthm.2016.01.019.

268. Packer M, Fowler MB, Roecker EB, et al.; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194-9. doi:10.1161/01.cir.0000035653.72855.bf.

269. Poole-Wilson PA, Swedberg K, Cleland JG, et al.; Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7-13. doi:10.1016/S0140-6736(03)13800-7.

270. Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337(22):1576-83. doi:10.1056/NEJM199711273372202.

271. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21(24):2071-8. doi:10.1053/euhj.2000.2476.

272. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101(11):1297-302. doi:10.1161/01.cir.101.11.1297.

273. Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102(7):748-54. doi:10.1161/01.cir.102.7.748.

274. Oseroff O, Retyk E, Bochoeyer A. Subanalyses of secondary prevention implantable cardioverter-defibrillator trials: antiarrhythmics versus implantable defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH). Curr Opin Cardiol. 2004;19(1):26-30. doi:10.1097/00001573-200401000-00007.

275. From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR), Society of NeuroInterventional Surgery (SNIS), and World Stroke Organization (WSO); Sacks D, Baxter B, Campbell BCV, et al. Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke. 2018;13(6):612-32. doi:10.1177/1747493018778713.

276. Shen L, Jhund PS, Petrie MC, et al. Declining Risk of Sudden Death in Heart Failure. N Engl J Med. 2017;377(1):41-51. doi:10.1056/NEJMoa1609758.

277. Valembois L, Audureau E, Takeda A, et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019;9(9):CD005049. doi:10.1002/14651858.CD005049.pub5.

278. Køber L, Torp-Pedersen C, McMurray JJ, et al.; Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25): 2678-87. doi:10.1056/NEJMoa0800456. Erratum in: N Engl J Med. 2010;363(14):1384.

279. Koplan BA, Kaplan AJ, Weiner S, et al. Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing necessary? J Am Coll Cardiol. 2009 J;53(4):355-60. doi:10.1016/j.jacc.2008.09.043.

280. Connolly SJ, Dorian P, Roberts RS, et al.; Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295(2):165-71. doi:10.1001/jama.295.2.165.

281. Sapp JL, Wells GA, Parkash R, et al. Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. N Engl J Med. 2016;375(2):111-21. doi:10.1056/NEJMoa1513614.

282. Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm. 2010;7(7):865-9. doi:10.1016/j.hrthm.2010.03.036.

283. Penela D, Van Huls Van Taxis C, Aguinaga L, et al. Neurohormonal, structural, and functional recovery pattern after premature ventricular complex ablation is independent of structural heart disease status in patients with depressed left ventricular ejection fraction: a prospective multicenter study. J Am Coll Cardiol. 2013;62(13):1195-202. doi:10.1016/j.jacc.2013.06.012. Erratum in: J Am Coll Cardiol. 2014;63(7):746. doi:10.1016/j.jacc.2014.01.001.

284. Lee A, Denman R, Haqqani HM. Ventricular Ectopy in the Context of Left Ventricular Systolic Dysfunction: Risk Factors and Outcomes Following Catheter Ablation. Heart Lung Circ. 2019;28(3):379-88. doi:10.1016/j.hlc.2018.01.012.

285. Mountantonakis SE, Frankel DS, Gerstenfeld EP, et al. Reversal of outflow tract ventricular premature depolarization-induced cardiomyopathy with ablation: effect of residual arrhythmia burden and preexisting cardiomyopathy on outcome. Heart Rhythm. 2011;8(10):1608-14. doi:10.1016/j.hrthm.2011.04.026.

286. Oomen AWGJ, Dekker LRC, Meijer A. Catheter ablation of symptomatic idiopathic ventricular arrhythmias : A five-year single-centre experience. Neth Heart J. 2018;26(4):210-6. doi:10.1007/s12471-018-1085-5.

287. Zang M, Zhang T, Mao J, et al. Beneficial effects of catheter ablation of frequent premature ventricular complexes on left ventricular function. Heart. 2014;100(10):787-93. doi:10.1136/heartjnl-2013-305175.

288. Bogun F, Crawford T, Reich S, et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm. 2007;4(7):863-7. doi:10.1016/j.hrthm.2007.03.003.

289. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333(2):77-82. doi:10.1056/NEJM199507133330201.

290. Hyman MC, Mustin D, Supple G, et al. Class IC antiarrhythmic drugs for suspected premature ventricular contraction-induced cardiomyopathy. Heart Rhythm. 2018;15(2):159-63. doi:10.1016/j.hrthm.2017.12.018.

291. Di Marco A, Anguera I, Schmitt M, et al. Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy: Systematic Review and Meta-Analysis. JACC Heart Fail. 2017;5(1):28-38. doi:10.1016/j.jchf.2016.09.017. Erratum in: JACC Heart Fail. 2017;5(4):316. doi:10.1016/j.jchf.2017.02.006.

292. Klem I, Klein M, Khan M, et al. Relationship of LVEF and Myocardial Scar to Long-Term Mortality Risk and Mode of Death in Patients With Nonischemic Cardiomyopathy. Circulation. 2021;143(14):1343-58. doi:10.1161/CIRCULATIONAHA.120.048477.

293. Francone M. Role of cardiac magnetic resonance in the evaluation of dilated cardiomyopathy: diagnostic contribution and prognostic significance. ISRN Radiol. 2014;2014:365404. doi:10.1155/2014/365404.

294. Link MS, Costeas XF, Griffith JL, et al. High incidence of appropriate implantable cardioverter-defibrillator therapy in patients with syncope of unknown etiology and inducible ventricular arrhythmias. J Am Coll Cardiol. 1997;29(2):370-5. doi:10.1016/s0735-1097(96)00477-9.

295. Goldberger JJ, Subačius H, Patel T, et al. Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2014;63(18):1879-89. doi:10.1016/j.jacc.2013.12.021.

296. Chatterjee S, Ghosh J, Lichstein E, et al. Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. Am J Cardiol. 2012;110(4):607-13. doi:10.1016/j.amjcard.2012.04.034.

297. Atti V, Vuddanda V, Turagam MK, et al. Prophylactic catheter ablation of ventricular tachycardia in ischemic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials. J Interv Card Electrophysiol. 2018;53(2):207-15. doi:10.1007/s10840-018-0376-5.

298. Santangeli P, Muser D, Maeda S, et al. Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: A systematic review and meta-analysis of randomized controlled trials. Heart Rhythm. 2016;13(7):1552-9. doi:10.1016/j.hrthm.2016.03.004.

299. Dinov B, Fiedler L, Schönbauer R, et al. Outcomes in catheter ablation of ventricular tachycardia in dilated nonischemic cardiomyopathy compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) Study. Circulation. 2014;129(7):728-36. doi:10.1161/CIRCULATIONAHA.113.003063.

300. Blanck Z, Dhala A, Deshpande S, et al. Bundle branch reentrant ventricular tachycardia: cumulative experience in 48 patients. J Cardiovasc Electrophysiol. 1993;4(3):253-62. doi:10.1111/j.1540-8167.1993.tb01228.x.

301. Caceres J, Jazayeri M, McKinnie J, et al. Sustained bundle branch reentry as a mechanism of clinical tachycardia. Circulation. 1989;79(2):256-70. doi:10.1161/01.cir.79.2.256.

302. Proietti R, Essebag V, Beardsall J, et al. Substrate-guided ablation of haemodynamically tolerated and untolerated ventricular tachycardia in patients with structural heart disease: effect of cardiomyopathy type and acute success on long-term outcome. Europace. 2015;17(3):461-7. doi:10.1093/europace/euu326.

303. Tzou WS, Tung R, Frankel DS, et al. Ventricular Tachycardia Ablation in Severe Heart Failure: An International Ventricular Tachycardia Ablation Center Collaboration Analysis. Circ Arrhythm Electrophysiol. 2017;10(1):e004494. doi:10.1161/CIRCEP.116.004494. Erratum in: Circ Arrhythm Electrophysiol. 2018;11(8):e000029. doi:10.1161/HAE.0000000000000029.

304. Maury P, Baratto F, Zeppenfeld K, et al. Radio-frequency ablation as primary management of well-tolerated sustained monomorphic ventricular tachycardia in patients with structural heart disease and left ventricular ejection fraction over 30%. Eur Heart J. 2014;35(22):1479-85. doi:10.1093/eurheartj/ehu040.

305. Clemens M, Peichl P, Wichterle D, et al. Catheter Ablation of Ventricular Tachycardia as the First-Line Therapy in Patients With Coronary Artery Disease and Preserved Left Ventricular Systolic Function: Long-Term Results. J Cardiovasc Electrophysiol. 2015;26(10):1105-10. doi:10.1111/jce.12751.

306. Tung R, Vaseghi M, Frankel DS, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: An International VT Ablation Center Collaborative Group study. Heart Rhythm. 2015;12(9):1997-2007. doi:10.1016/j.hrthm.2015.05.036.

307. Muser D, Santangeli P, Castro SA, et al. Long-Term Outcome After Catheter Ablation of Ventricular Tachycardia in Patients With Nonischemic Dilated Cardiomyopathy. Circ Arrhythm Electrophysiol. 2016;9(10):e004328. doi:10.1161/CIRCEP.116.004328.

308. Ebert M, Wijnmaalen AP, de Riva M, et al. Prevalence and Prognostic Impact of Pathogenic Variants in Patients With Dilated Cardiomyopathy Referred for Ventricular Tachycardia Ablation. JACC Clin Electrophysiol. 2020;6(9):1103-14. doi:10.1016/j.jacep.2020.04.025.

309. Smit MD, Moes ML, Maass AH, et al. The importance of whether atrial fibrillation or heart failure develops first. Eur J Heart Fail. 2012 Sep;14(9):1030-40. doi:10.1093/eurjhf/hfs097.

310. Swedberg K, Olsson LG, Charlesworth A, et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J. 2005;26(13):1303-8. doi:10.1093/eurheartj/ehi166.

311. Hoppe UC, Casares JM, Eiskjaer H, et al. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation. 2006;114(1):18-25. doi:10.1161/CIRCULATIONAHA.106.614560.

312. Calvo N, Bisbal F, Guiu E, et al. Impact of atrial fibrillation-induced tachycardiomyopathy in patients undergoing pulmonary vein isolation. Int J Cardiol. 2013;168(4):4093-7. doi:10.1016/j.ijcard.2013.07.017.

313. Morris PD, Robinson T, Channer KS. Reversible heart failure: toxins, tachycardiomyopathy and mitochondrial abnormalities. Postgrad Med J. 2012;88(1046):706-12. doi:10.1136/postgradmedj-2011-130698.

314. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-72. doi:10.1378/chest.09-1584.

315. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. doi:10.1136/bmj.d124.

316. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500-10. doi:10.1093/eurheartj/ehr488.

317. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. doi:10.1056/NEJMoa0905561. Erratum in: N Engl J Med. 2010;363(19):1877.

318. Granger CB, Alexander JH, McMurray JJ, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. doi:10.1056/NEJMoa1107039.

319. Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. doi:10.1056/NEJMoa1009638.

320. Giugliano RP, Ruff CT, Braunwald E, et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104. doi:10.1056/NEJMoa1310907.

321. Shin SY, Han SJ, Kim JS, et al. Identification of Markers Associated With Development of Stroke in "Clinically Low-Risk" Atrial Fibrillation Patients. J Am Heart Assoc. 2019;8(21):e012697. doi:10.1161/JAHA.119.012697.

322. Nielsen PB, Larsen TB, Skjøth F, et al. Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. Sci Rep. 2016;6:27410. doi:10.1038/srep27410.

323. Eikelboom JW, Connolly SJ, Brueckmann M, et al.; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206-14. doi:10.1056/NEJMoa1300615.

324. Carnicelli AP, De Caterina R, Halperin JL, et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation. 2017;135(13):1273-5. doi:10.1161/CIRCULATIONAHA.116.026714.

325. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62. doi:10.1016/S0140-6736(13)62343-0.

326. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100(4):376-80. doi:10.1161/01.cir.100.4.376.

327. McMurray J, Køber L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol. 2005;45(4):525-30. doi:10.1016/j.jacc.2004.09.076.

328. Swedberg K, Zannad F, McMurray JJ, et al.; EMPHASIS-HF Study Investigators. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASISHF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol. 2012;59(18):1598-603. doi:10.1016/j.jacc.2011.11.063.

329. Han M, Zhang Y, Sun S, et al. Renin-angiotensin system inhibitors prevent the recurrence of atrial fibrillation: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol. 2013;62(4):405-15. doi:10.1097/FJC.0b013e3182a094a1.

330. Brodsky MA, Allen BJ, Walker CJ 3rd, et al. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol. 1987;60(7):572-5. doi:10.1016/0002-9149(87)90307-9.

331. Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation. 1998;98(23):2574-9. doi:10.1161/01.cir.98.23.2574.

332. Shelton RJ, Clark AL, Goode K, et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart. 2009;95(11):924-30. doi:10.1136/hrt.2008.158931.

333. Capucci A, Villani GQ, Aschieri D, et al. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J. 2000;21(1):66-73. doi:10.1053/euhj.1999.1734.

334. Hagens VE, Crijns HJ, Van Veldhuisen DJ, et al.; RAte Control versus Electrical cardioversion for persistent atrial fibrillation study group. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J. 2005;149(6):1106-11. doi:10.1016/j.ahj.2004.11.030.

335. Van Gelder IC, Hagens VE, Bosker HA, et al.; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834-40. doi:10.1056/NEJMoa021375.

336. Hofmann R, Steinwender C, Kammler J, et al. Effects of a high dose intravenous bolus amiodarone in patients with atrial fibrillation and a rapid ventricular rate. Int J Cardiol. 2006;110(1):27-32. doi:10.1016/j.ijcard.2005.06.048.

337. Hofmann R, Wimmer G, Leisch F. Intravenous amiodarone bolus immediately controls heart rate in patients with atrial fibrillation accompanied by severe congestive heart failure. Heart. 2000;84(6):635. doi:10.1136/heart.84.6.635.

338. Van Gelder IC, Wyse DG, Chandler ML, et al.; RACE and AFFIRM Investigators. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace. 2006;8(11):935-42. doi:10.1093/europace/eul106.

339. Li SJ, Sartipy U, Lund LH, et al. Prognostic Significance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry. Circ Heart Fail. 2015;8(5):871-9. doi:10.1161/CIRCHEARTFAILURE.115.002285.

340. Segal JB, McNamara RL, Miller MR, et al. The evidence regarding the drugs used for ventricular rate control. J Fam Pract. 2000;49(1):47-59.

341. Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451. doi:10.1136/bmj.h4451. Erratum in: BMJ. 2015;351:h4937. doi:10.1136/bmj.h4937.

342. Sethi NJ, Nielsen EE, Safi S, et al. Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. PLoS One. 2018;13(3):e0193924. doi:10.1371/journal.pone.0193924.

343. Chatterjee NA, Upadhyay GA, Ellenbogen KA, et al. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis and systematic review. Circ Arrhythm Electrophysiol. 2012;5(1):68-76. doi:10.1161/CIRCEP.111.967810.

344. Brignole M, Botto G, Mont L, et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J. 2011;32(19):2420-9. doi:10.1093/eurheartj/ehr162.

345. Brignole M, Pentimalli F, Palmisano P, et al.; APAF-CRT Trial Investigators. AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. Eur Heart J. 2021;42(46):4731-9. doi:10.1093/eurheartj/ehab569. Erratum in: Eur Heart J. 2021;42(46):4768. doi:10.1093/eurheartj/ehab669. Erratum in: Eur Heart J. 2022;43(5):386. doi:10.1093/eurheartj/ehab831.

346. Stavrakis S, Garabelli P, Reynolds DW. Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a meta-analysis. Europace. 2012;14(10):1490-7. doi:10.1093/europace/eus193.

347. Ousdigian KT, Borek PP, Koehler JL, et al. The epidemic of inadequate biventricular pacing in patients with persistent or permanent atrial fibrillation and its association with mortality. Circ Arrhythm Electrophysiol. 2014;7(3):370-6. doi:10.1161/CIRCEP.113.001212.

348. Hayes DL, Boehmer JP, Day JD, et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm. 2011;8(9):1469-75. doi:10.1016/j.hrthm.2011.04.015.

349. Tang AS, Wells GA, Talajic M, et al.; Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363(25):2385-95. doi:10.1056/NEJMoa1009540.

350. Gasparini M, Leclercq C, Lunati M, et al. Cardiac resynchronization therapy in patients with atrial fibrillation: the CERTIFY study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail. 2013;1(6):500-7. doi:10.1016/j.jchf.2013.06.003.

351. Ganesan AN, Brooks AG, Roberts-Thomson KC, et al. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure a systematic review. J Am Coll Cardiol. 2012;59(8):719-26. doi:10.1016/j.jacc.2011.10.891.

352. Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Am Heart J. 2002;144(4):597-607.

353. Marrouche NF, Brachmann J, Andresen D, et al.; CASTLE-AF Investigators. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018;378(5):417-27. doi:10.1056/NEJMoa1707855.

354. Packer DL, Mark DB, Robb RA, et al.; CABANA Investigators. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1261-74. doi:10.1001/jama.2019.0693.

355. Chen C, Zhou X, Zhu M, et al. Catheter ablation versus medical therapy for patients with persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized controlled trials. J Interv Card Electrophysiol. 2018;52(1):9-18. doi:10.1007/s10840-018-0349-8.

356. Bardy GH, Lee KL, Mark DB, et al.; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-37. doi:10.1056/NEJMoa043399. Erratum in: N Engl J Med. 2005;352(20):2146.

357. Packer M, Coats AJ, Fowler MB, et al.; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651-8. doi:10.1056/NEJM200105313442201.

358. Schmieder RE, Rockstroh JK. Efficacy and tolerance of low-dose loop diuretics in hypertension. Cardiology. 1994;84 Suppl 2:36-42. doi:10.1159/000176455.

359. Spannbrucker N, Achhammer I, Metz P, Glocke M. Comparative study on the antihypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Arzneimittelforschung. 1988;38(1A):190-3.

360. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 — effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis. J Hypertens. 2018;36(8):1637-47. doi:10.1097/HJH.0000000000001777.

361. Cohn JN, Pfeffer MA, Rouleau J, et al.; MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5(5):659-67. doi:10.1016/s1388-9842(03)00163-6.

362. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000;283(15):1967-75. Erratum in: JAMA 2002;288(23):2976.

363. Dorszewski A, Göhmann E, Dorsźewski B, et al. Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study. J Card Fail. 1997;3(2):91-6. doi:10.1016/s1071-9164(97)90040-3.

364. Bayliss J, Norell MS, Canepa-Anson R, et al. Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin. Br Med J (Clin Res Ed). 1985;290(6485):1861-5. doi:10.1136/bmj.290.6485.1861.

365. Tavazzi L, Maggioni AP, Marchioli R, et al.; Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231-9. doi:10.1016/S0140-6736(08)61240-4.

366. Kjekshus J, Apetrei E, Barrios V, et al.; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248-61. doi:10.1056/NEJMoa0706201.

367. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169): 2001-7.

368. Fox K, Ford I, Steg PG, et al.; BEAUTIFUL Investigators. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009;30(19):2337-45. doi:10.1093/eurheartj/ehp358.

369. Vitale C, Spoletini I, Malorni W, et al. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina--the VASCO-angina study. Int J Cardiol. 2013;168(2):1078-81. doi:10.1016/j.ijcard.2012.11.001.

370. Vitale C, Wajngaten M, Sposato B, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J. 2004;25(20):1814-21. doi:10.1016/j.ehj.2004.06.034.

371. Gao D, Ning N, Niu X, et al. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 2011;97(4):278-86. doi:10.1136/hrt.2010.208751.

372. Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLINTIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol. 2009;53(17):1510-6. doi:10.1016/j.jacc.2009.01.037.

373. Wei J, Wu T, Yang Q, et al. Nitrates for stable angina: a systematic review and meta-analysis of randomized clinical trials. Int J Cardiol. 2011;146(1):4-12. doi:10.1016/j.ijcard.2010.05.019.

374. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314(24):1547-52. doi:10.1056/NEJM198606123142404.

375. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail. 1999;5(3):178-87. doi:10.1016/s1071-9164(99)90001-5.

376. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325(5):303-10. doi:10.1056/NEJM199108013250502.

377. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002;359(9314): 1269-75. doi:10.1016/S0140-6736(02)08265-X. Erratum in: Lancet 2002;360(9335):806.

378. Perera D, Clayton T, O’Kane PD, et al.; REVIVED-BCIS2 Investigators. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction. N Engl J Med. 2022; 387(15):1351-60. doi:10.1056/NEJMoa2206606.

379. Velazquez EJ, Lee KL, Jones RH, et al.; STICHES Investigators. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med. 2016;374(16):1511-20. doi:10.1056/NEJMoa1602001.

380. Packer M, Anker SD, Butler J, et al. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation. 2021;143(4):326-36. doi:10.1161/CIRCULATIONAHA.120.051783. Erratum in: Circulation. 2021;143(4):e30. doi:10.1161/CIR.0000000000000954.

381. Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111(5):583-90. doi:10.1161/01.CIR.0000154542.13412.B1.

382. Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28(10):2345-51. doi:10.2337/diacare.28.10.2345.

383. MacDonald MR, Eurich DT, Majumdar SR, et al. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U. K. General Practice Research Database. Diabetes Care. 2010 33(6):1213-8. doi:10.2337/dc09-2227.

384. Boussageon R, Supper I, Bejan-Angoulvant T, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med. 2012;9(4):e1001204. doi:10.1371/journal.pmed.

385. Home PD, Pocock SJ, Beck-Nielsen H, et al.; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-35. doi:10.1016/S0140-6736(09)60953-3.

386. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-26. doi:10.1056/NEJMoa1307684.

387. Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232-42. doi:10.1056/NEJMoa1501352. Erratum in: N Engl J Med. 2015;373(6):586. doi:10.1056/NEJMx150029.

388. Rosenstock J, Perkovic V, Johansen OE, et al.; CARMELINA Investigators. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69-79. doi:10.1001/jama.2018.18269.

389. McGuire DK, Van de Werf F, Armstrong PW, et al.; Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2016;1(2):126-35. doi:10.1001/jamacardio.2016.0103.

390. Holman RR, Bethel MA, Mentz RJ, et al.; EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(13):1228-39. doi:10.1056/NEJMoa1612917.

391. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22. doi:10.1056/NEJMoa1603827.

392. Pfeffer MA, Claggett B, Diaz R, et al.; ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373(23):2247-57. doi:10.1056/NEJMoa1509225.

393. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-44. doi:10.1056/NEJMoa1607141.

394. Husain M, Birkenfeld AL, Donsmark M, et al.; PIONEER 6 Investigators. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841-51. doi:10.1056/NEJMoa1901118.

395. Gerstein HC, Colhoun HM, Dagenais GR, et al.; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-30. doi:10.1016/S0140-6736(19)31149-3.

396. Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69-77. doi:10.1002/ejhf.657.

397. Margulies KB, Hernandez AF, Redfield MM, et al.; NHLBI Heart Failure Clinical Research Network. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2016;316(5):500-8. doi:10.1001/jama.2016.10260.

398. Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20(1):189. doi:10.1186/s12933-021-01366-8.

399. Hawkins NM, MacDonald MR, Petrie MC, et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail. 2009;11(7):684-90. doi:10.1093/eurjhf/hfp066.

400. Lainscak M, Podbregar M, Kovacic D, et al. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respir Med. 2011;105 Suppl 1:S44-9. doi:10.1016/S0954-6111(11)70010-5.

401. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55(17):1780-7. doi:10.1016/j.jacc.2010.01.024.

402. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;2005(4):CD003566. doi:10.1002/14651858.CD003566.pub2.

403. Düngen HD, Apostolovic S, Inkrot S, et al.; CIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart Failure. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail. 2011;13(6):670-80. doi:10.1093/eurjhf/hfr020.

404. Tavazzi L, Swedberg K, Komajda M, et al.; SHIFT Investigators. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. Int J Cardiol. 2013;170(2):182-8. doi:10.1016/j.ijcard.2013.10.068.

405. Swedberg K, Young JB, Anand IS, et al.; RED-HF Committees; RED-HF Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013;368(13):1210-9. doi:10.1056/NEJMoa1214865.

406. Lewis GD, Malhotra R, Hernandez AF, et al.; NHLBI Heart Failure Clinical Research Network. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. JAMA. 2017;317(19):1958-66. doi:10.1001/jama.2017.5427. Erratum in: JAMA. 2017;317(23):2453. doi:10.1001/jama.2017.7019.

407. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al.; CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J. 2015;36(11):657-68. doi:10.1093/eurheartj/ehu385.

408. Ponikowski P, Kirwan BA, Anker SD, et al.; AFFIRM-AHF investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895-904. doi:10.1016/S0140-6736(20)32339-4. Erratum in: Lancet. 2021;398(10315):1964. doi:10.1016/S0140-6736(21)02492-2.

409. Kalra PR, Cleland JGF, Petrie MC, et al.; IRONMAN Study Group. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10369):2199-209. doi:10.1016/S0140-6736(22)02083-9.

410. Comin-Colet J, Lainscak M, Dickstein K, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Eur Heart J. 2013;34(1):30-8. doi:10.1093/eurheartj/ehr504.

411. Anker SD, Comin Colet J, et al.; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-48. doi:10.1056/NEJMoa0908355.

412. Graham FJ, Pellicori P, Kalra PR, et al.Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis. Eur J Heart Fail. 2023;25(4):528-37. doi:10.1002/ejhf.2810.

413. Salah HM, Savarese G, Rosano GMC, et al. Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis. ESC Heart Fail. 2023;10(2):1473-80. doi:10.1002/ehf2.14310.

414. Vukadinović D, Abdin A, Emrich I, et al. Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis. Clin Res Cardiol. 2023;112(7):954-66. doi:10.1007/s00392-023-02207-2.

415. Anker SD, Khan MS, Butler J, et al. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta-analysis. Eur J Heart Fail. 2023;25(7):1080-90. doi:10.1002/ejhf.2860.

416. White WB, Saag KG, Becker MA, et al.; CARES Investigators. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018;378(13):1200-10. doi:10.1056/NEJMoa1710895.

417. Arfè A, Scotti L, Varas-Lorenzo C, et al.; Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016;354:i4857. doi:10.1136/bmj.i4857.

418. Verma S, Eikelboom JW, Nidorf SM, et al. Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2015;15:96. doi:10.1186/s12872-015-0068-3.

419. Maurer MS, Schwartz JH, Gundapaneni B, et al.; ATTR-ACT Study Investigators. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007-16. doi:10.1056/NEJMoa1805689.

420. Gundapaneni BK, Sultan MB, Keohane DJ, Schwartz JH. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2018;25(3):464-8. doi:10.1111/ene.13510.

421. Damy T, Garcia-Pavia P, Hanna M, et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021;23(2):277-85. doi:10.1002/ejhf.2027.

422. Sultan MB, Gundapaneni B, Schumacher J, Schwartz JH. Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy. Clin Med Insights Cardiol. 2017;11:1179546817730322. doi:10.1177/1179546817730322.

423. Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006;48(8):1527-37. doi:10.1016/j.jacc.2006.06.055.

424. Glassman AH. Cardiovascular effects of tricyclic antidepressants. Annu Rev Med. 1984;35:503-11. doi:10.1146/annurev.me.35.020184.002443.

425. Pacher P, Ungvari Z, Nanasi PP, et al. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem. 1999;6(6):469-80.

426. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441(3):137-40. doi:10.1016/s0014-2999(02)01532-7.

427. O’Connor CM, Jiang W, Kuchibhatla M, et al.; SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHARTCHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010;56(9):692-9. doi:10.1016/j.jacc.2010.03.068.

428. Angermann CE, Gelbrich G, Störk S, et al.; MOOD-HF Study Investigators and Committee Members. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. JAMA. 2016;315(24):2683-93. doi:10.1001/jama.2016.7635.

429. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002;162(15):1682-8. doi:10.1001/archinte.162.15.1682.

430. Seo WW, Park JJ, Park HA, et al. Guideline-directed medical therapy in elderly patients with heart failure with reduced ejection fraction: a cohort study. BMJ Open. 2020;10(2):e030514. doi:10.1136/bmjopen-2019-030514.

431. Flather MD, Shibata MC, Coats AJ, et al.; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215-25. doi:10.1093/eurheartj/ehi115.

432. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397-402. doi:10.1056/NEJMoa020265.

433. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000;35(6):1628-37. doi:10.1016/s0735-1097(00)00582-9.

434. Anker SD, Butler J, Filippatos G, et al.; EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-61. doi:10.1056/NEJMoa2107038.

435. Solomon SD, McMurray JJV, Claggett B, et al.; DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089-98. doi:10.1056/NEJMoa2206286.

436. Solomon SD, Vaduganathan M, L Claggett B, et al. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2020;141(5):352-61. doi:10.1161/CIRCULATIONAHA.119.044586.

437. Mc Causland FR, Lefkowitz MP, Claggett B, et al. Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation. 2020;142(13):1236-45. doi:10.1161/CIRCULATIONAHA.120.047643.

438. Cleland JGF, Bunting KV, Flather MD, et al.; Beta-blockers in Heart Failure Collaborative Group. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39(1):26-35. doi:10.1093/eurheartj/ehx564.

439. Solomon SD, Claggett B, Lewis EF, et al.; TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37(5):455-62. doi:10.1093/eurheartj/ehv464.

440. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114(5):397-403. doi:10.1161/CIRCULATIONAHA.106.628347.

441. Faris RF, Flather M, Purcell H, et al. Diuretics for heart failure. Cochrane Database Syst Rev. 2012;(2):CD003838. doi:10.1002/14651858.CD003838.pub3. Update in: Cochrane Database Syst Rev. 2016;4:CD003838. doi:10.1002/14651858.CD003838.pub4.

442. Pitt B, Pfeffer MA, Assmann SF, et al.; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-92. doi:10.1056/NEJMoa1313731.

443. Myhre PL, Vaduganathan M, Claggett BL, et al. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. JAMA Cardiol. 2018;3(10):1000-5. doi:10.1001/jamacardio.2018.2568.

444. Cleland JG, Tendera M, Adamus J, et al.; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338-45. doi:10.1093/eurheartj/ehl250.

445. Yusuf S, Pfeffer MA, Swedberg K, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777-81. doi:10.1016/S0140-6736(03)14285-7.

446. Mulder BA, van Veldhuisen DJ, Crijns HJ, et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. Eur J Heart Fail. 2012;14(10):1171-8. doi:10.1093/eurjhf/hfs100.

447. van Veldhuisen DJ, Cohen-Solal A, Böhm M, et al.; SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol. 2009;53(23):2150-8. doi:10.1016/j.jacc.2009.02.046.

448. Hernandez AF, Hammill BG, O’Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol. 2009;53(2):184-92. doi:10.1016/j.jacc.2008.09.031.

449. Martin N, Manoharan K, Thomas J, et al. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database Syst Rev. 2018;6(6):CD012721. doi:10.1002/14651858.CD012721.pub2. Update in: Cochrane Database Syst Rev. 2021;5:CD012721. doi:10.1002/14651858.CD012721.pub3.

450. McMurray JJ, Ostergren J, Swedberg K, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767-71. doi:10.1016/S0140-6736(03)14283-3.

451. Park S, Ahn JM, Kim TO, et al.; IRIS-MAIN Registry Investigators. Revascularization in Patients With Left Main Coronary Artery Disease and Left Ventricular Dysfunction. J Am Coll Cardiol. 2020;76(12):1395-406. doi:10.1016/j.jacc.2020.07.047.

452. Marui A, Kimura T, Nishiwaki N, et al.; CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Comparison of five-year outcomes of coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular ejection fractions≤50% versus >50% (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). Am J Cardiol. 2014;114(7):988-96. doi:10.1016/j.amjcard.2014.07.007.

453. Gaudino M, Hameed I, Khan FM, et al. Treatment strategies in ischaemic left ventricular dysfunction: a network meta-analysis. Eur J Cardiothorac Surg. 2020:ezaa319. doi:10.1093/ejcts/ezaa319.

454. Mehta P, Imamura T, Juricek C, et al. Combined Left Ventricular Assist Device and Coronary Artery Bypass Grafting Surgery: Should We Bypass the Bypass? ASAIO J. 2020;66(1):32-7. doi:10.1097/MAT.0000000000000956.

455. Potapov EV, Antonides C, Crespo-Leiro MG, et al. 2019 EACTS Expert Consensus on long-term mechanical circulatory support. Eur J Cardiothorac Surg. 2019;56(2):230-70. doi:10.1093/ejcts/ezz098.

456. Bangalore S, Guo Y, Samadashvili Z, et al. Revascularization in Patients With Multivessel Coronary Artery Disease and Severe Left Ventricular Systolic Dysfunction: Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery. Circulation. 2016;133(22):2132-40. doi:10.1161/CIRCULATIONAHA.115.021168.

457. Smith CR, Leon MB, Mack MJ, et al.; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187-98. doi:10.1056/NEJMoa1103510.

458. Levy F, Laurent M, Monin JL, et al. Aortic valve replacement for low-flow/low-gradient aortic stenosis operative risk stratification and long-term outcome: a European multicenter study. J Am Coll Cardiol. 2008;51(15):1466-72. doi:10.1016/j.jacc.2007.10.067.

459. Monin JL, Quéré JP, Monchi M, et al. Low-gradient aortic stenosis: operative risk stratification and predictors for long-term outcome: a multicenter study using dobutamine stress hemodynamics. Circulation. 2003;108(3):319-24. doi:10.1161/01.CIR.0000079171.43055.46.

460. Wacławski J, Wilczek K, Hudzik B, et al. Aortic balloon valvuloplasty as a bridge-to-decision in patients with aortic stenosis. Postepy Kardiol Interwencyjnej. 2019;15(2):195-202. doi:10.5114/aic.2019.86012.

461. Zhong J, Kamp N, Bansal A, et al. Balloon Aortic Valvuloplasty in the Modern Era: A Review of Outcomes, Indications, and Technical Advances. J Soc Cardiovasc Angiogr Interv. 2023;2(4):101002. doi:10.1016/j.jscai.2023.101002.

462. Chaliki HP, Mohty D, Avierinos JF, et al. Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function. Circulation. 2002;106(21):2687-93. doi:10.1161/01.cir.0000038498.59829.38.

463. Tornos P, Sambola A, Permanyer-Miralda G, et al. Long-term outcome of surgically treated aortic regurgitation: influence of guideline adherence toward early surgery. J Am Coll Cardiol. 2006;47(5):1012-7. doi:10.1016/j.jacc.2005.10.049.

464. Kaneko T, Ejiofor JI, Neely RC, et al. Aortic Regurgitation With Markedly Reduced Left Ventricular Function Is Not a Contraindication for Aortic Valve Replacement. Ann Thorac Surg. 2016;102(1):41-7. doi:10.1016/j.athoracsur.2015.12.068.

465. Dujardin KS, Enriquez-Sarano M, Schaff HV, et al. Mortality and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study. Circulation. 1999;99(14):1851-7. doi:10.1161/01.cir.99.14.1851.

466. Klodas E, Enriquez-Sarano M, Tajik AJ, et al. Optimizing timing of surgical correction in patients with severe aortic regurgitation: role of symptoms. J Am Coll Cardiol. 1997;30(3):746-52. doi:10.1016/s0735-1097(97)00205-2.

467. Yoon SH, Schmidt T, Bleiziffer S, et al. Transcatheter Aortic Valve Replacement in Pure Native Aortic Valve Regurgitation. J Am Coll Cardiol. 2017;70(22):2752-63. doi:10.1016/j.jacc.2017.10.006.

468. Jung JC, Jang MJ, Hwang HY. Meta-Analysis Comparing Mitral Valve Repair Versus Replacement for Degenerative Mitral Regurgitation Across All Ages. Am J Cardiol. 2019;123(3):446-53. doi:10.1016/j.amjcard.2018.10.024.

469. Lazam S, Vanoverschelde JL, Tribouilloy C, et al.; MIDA (Mitral Regurgitation International Database) Investigators. Twenty-Year Outcome After Mitral Repair Versus Replacement for Severe Degenerative Mitral Regurgitation: Analysis of a Large, Prospective, Multicenter, International Registry. Circulation. 2017;135(5):410-22. doi:10.1161/CIRCULATIONAHA.116.023340.

470. Chikwe J, Toyoda N, Anyanwu AC, et al. Relation of Mitral Valve Surgery Volume to Repair Rate, Durability, and Survival. J Am Coll Cardiol. 2017:S0735-1097(17)30677-0. doi:10.1016/j.jacc.2017.02.026.

471. David TE, David CM, Tsang W, et al. Long-Term Results of Mitral Valve Repair for Regurgitation Due to Leaflet Prolapse. J Am Coll Cardiol. 2019;74(8):1044-53. doi:10.1016/j.jacc.2019.06.052.

472. Feldman T, Foster E, Glower DD, et al.; EVEREST II Investigators. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364(15):1395-406. doi:10.1056/NEJMoa1009355. Erratum in: N Engl J Med. 2011;365(2):189.

473. Buzzatti N, Van Hemelrijck M, Denti P, et al. Transcatheter or surgical repair for degenerative mitral regurgitation in elderly patients: A propensity-weighted analysis. J Thorac Cardiovasc Surg. 2019;158(1):86-94.e1. doi:10.1016/j.jtcvs.2019.01.023.

474. Stone GW, Lindenfeld J, Abraham WT, et al.; COAPT Investigators. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. 2018;379(24):2307-18. doi:10.1056/NEJMoa1806640.

475. Coats AJS, Anker SD, Baumbach A, et al. The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. Eur Heart J. 2021;42(13):1254-69. doi:10.1093/eurheartj/ehab086.

476. Godino C, Munafò A, Scotti A, et al. MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry. J Heart Lung Transplant. 2020;39(12):1353-62. doi:10.1016/j.healun.2020.09.005.

477. Dreyfus GD, Corbi PJ, Chan KM, Bahrami T. Secondary tricuspid regurgitation or dilatation: which should be the criteria for surgical repair? Ann Thorac Surg. 2005;79(1):127-32. doi:10.1016/j.athoracsur.2004.06.057.

478. Van de Veire NR, Braun J, Delgado V, et al. Tricuspid annuloplasty prevents right ventricular dilatation and progression of tricuspid regurgitation in patients with tricuspid annular dilatation undergoing mitral valve repair. J Thorac Cardiovasc Surg. 2011;141(6):1431-9. doi:10.1016/j.jtcvs.2010.05.050.

479. Chikwe J, Itagaki S, Anyanwu A, Adams DH. Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation, Right Ventricular Function, and Pulmonary Artery Hypertension After Repair of Mitral Valve Prolapse. J Am Coll Cardiol. 2015;65(18):1931-8. doi:10.1016/j.jacc.2015.01.059.

480. Badhwar V, Rankin JS, He M, et al. Performing Concomitant Tricuspid Valve Repair at the Time of Mitral Valve Operations Is Not Associated With Increased Operative Mortality. Ann Thorac Surg. 2017;103(2):587-93. doi:10.1016/j.athoracsur.2016.06.004.

481. Brescia AA, Ward ST, Watt TMF, et al.; Michigan Mitral Research Group (MMRG). Outcomes of Guideline-Directed Concomitant Annuloplasty for Functional Tricuspid Regurgitation. Ann Thorac Surg. 2020;109(4):1227-32. doi:10.1016/j.athoracsur.2019.07.035.

482. Hamandi M, Smith RL, Ryan WH, et al. Outcomes of Isolated Tricuspid Valve Surgery Have Improved in the Modern Era. Ann Thorac Surg. 2019;108(1):11-5. doi:10.1016/j.athoracsur.2019.03.004.

483. Kadri AN, Menon V, Sammour YM, et al. Outcomes of patients with severe tricuspid regurgitation and congestive heart failure. Heart. 2019;105(23):1813-7. doi:10.1136/heartjnl-2019-315004.

484. Cazeau S, Leclercq C, Lavergne T, et al.; Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344(12):873-80. doi:10.1056/NEJM200103223441202.

485. Cleland JG, Daubert JC, Erdmann E, et al.; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539-49. doi:10.1056/NEJMoa050496.

486. Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J. 2006;27(16):1928-32. doi:10.1093/eurheartj/ehl099.

487. Cleland JG, Freemantle N, Erdmann E, et al. Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial. Eur J Heart Fail. 2012;14(6):628-34. doi:10.1093/eurjhf/hfs055.

488. Bristow MR, Saxon LA, Boehmer J, et al.; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140-50. doi:10.1056/NEJMoa032423.

489. Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013;34(46):3547-56. doi:10.1093/eurheartj/eht290.

490. Moss AJ, Hall WJ, Cannom DS, et al.; MADIT-CRT Trial Investigators. Cardiacresynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329-38. doi:10.1056/NEJMoa0906431.

491. Goldenberg I, Kutyifa V, Klein HU, et al. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med. 2014;370(18):1694-701. doi:10.1056/NEJMoa1401426.

492. Linde C, Abraham WT, Gold MR, et al.; REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52(23):1834-43. doi:10.1016/j.jacc.2008.08.027.

493. Daubert C, Gold MR, Abraham WT, et al.; REVERSE Study Group. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol. 2009;54(20):1837-46. doi:10.1016/j.jacc.2009.08.011.

494. Linde C, Gold MR, Abraham WT, et al.; REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction Study Group. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J. 2013;34(33):2592-9. doi:10.1093/eurheartj/eht160.

495. Woods B, Hawkins N, Mealing S, et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart. 2015;101(22):1800-6. doi:10.1136/heartjnl-2015-307634.

496. Curtis AB, Worley SJ, Adamson PB, et al.; Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK HF) Trial Investigators. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;368(17):1585-93. doi:10.1056/NEJMoa1210356.

497. Leclercq C, Walker S, Linde C, et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J. 2002;23(22):1780-7. doi:10.1053/euhj.2002.3232.

498. Brignole M, Pokushalov E, Pentimalli F, et al.; APAF-CRT Investigators. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J. 2018;39(45):3999-4008. doi:10.1093/eurheartj/ehy555.

499. Yin J, Hu H, Wang Y, et al. Effects of atrioventricular nodal ablation on permanent atrial fibrillation patients with cardiac resynchronization therapy: a systematic review and meta-analysis. Clin Cardiol. 2014;37(11):707-15. doi:10.1002/clc.22312.

500. Doshi RN, Daoud EG, Fellows C, et al.; PAVE Study Group. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol. 2005;16(11):1160-5. doi:10.1111/j.1540-8167.2005.50062.x.

501. Jones DG, Haldar SK, Hussain W, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol. 2013;61(18):1894-903. doi:10.1016/j.jacc.2013.01.069.

502. Gage RM, Burns KV, Bank AJ. Echocardiographic and clinical response to cardiac resynchronization therapy in heart failure patients with and without previous right ventricular pacing. Eur J Heart Fail. 2014;16(11):1199-205. doi:10.1002/ejhf.143.

503. Funck RC, Mueller HH, Lunati M, et al.; BioPace study group. Characteristics of a large sample of candidates for permanent ventricular pacing included in the Biventricular Pacing for Atrio-ventricular Block to Prevent Cardiac Desynchronization Study (BioPace). Europace. 2014;16(3):354-62. doi:10.1093/europace/eut343.

504. Beshai JF, Grimm RA, Nagueh SF, et al.; RethinQ Study Investigators. Cardiacresynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med. 2007;357(24):2461-71. doi:10.1056/NEJMoa0706695.

505. Steffel J, Robertson M, Singh JP, et al. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Eur Heart J. 2015;36(30):1983-9. doi:10.1093/eurheartj/ehv242.

506. Zusterzeel R, Selzman KA, Sanders WE, et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data. JAMA Intern Med. 2014;174(8):1340-8. doi:10.1001/jamainternmed.2014.2717.

507. Kusumoto FM, Calkins H, Boehmer J, et al.; Heart Rhythm Society; American College of Cardiology; American Heart Association. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. J Am Coll Cardiol. 2014;64(11):1143-77. doi:10.1016/j.jacc.2014.04.008.

508. Sharma PS, Dandamudi G, Herweg B, et al. Permanent His-bundle pacing as an alternative to biventricular pacing for cardiac resynchronization therapy: A multicenter experience. Heart Rhythm. 2018;15(3):413-20. doi:10.1016/j.hrthm.2017.10.014.

509. Vijayaraman P, Dandamudi G, Zanon F, et al. Permanent His bundle pacing: Recommendations from a Multicenter His Bundle Pacing Collaborative Working Group for standardization of definitions, implant measurements, and follow-up. Heart Rhythm. 2018;15(3):460-8. doi:10.1016/j.hrthm.2017.10.039.

510. Giraldi F, Cattadori G, Roberto M, et al. Long-term effectiveness of cardiac resynchronization therapy in heart failure patients with unfavorable cardiac veins anatomy comparison of surgical versus hemodynamic procedure. J Am Coll Cardiol. 2011;58(5):483-90. doi:10.1016/j.jacc.2011.02.065.

511. Barba-Pichardo R, Manovel Sánchez A, Fernández-Gómez JM, et al. Ventricular resynchronization therapy by direct His-bundle pacing using an internal cardioverter defibrillator. Europace. 2013;15(1):83-8. doi:10.1093/europace/eus228.

512. Huang W, Su L, Wu S, et al. Benefits of Permanent His Bundle Pacing Combined With Atrioventricular Node Ablation in Atrial Fibrillation Patients With Heart Failure With Both Preserved and Reduced Left Ventricular Ejection Fraction. J Am Heart Assoc. 2017;6(4):e005309. doi:10.1161/JAHA.116.005309.

513. Deshmukh P, Casavant DA, Romanyshyn M, Anderson K. Permanent, direct His-bundle pacing: a novel approach to cardiac pacing in patients with normal His-Purkinje activation. Circulation. 2000;101(8):869-77. doi:10.1161/01.cir.101.8.869.

514. Occhetta E, Bortnik M, Magnani A, et al. Prevention of ventricular desynchronization by permanent para-Hisian pacing after atrioventricular node ablation in chronic atrial fibrillation: a crossover, blinded, randomized study versus apical right ventricular pacing. J Am Coll Cardiol. 2006;47(10):1938-45. doi:10.1016/j.jacc.2006.01.056.

515. Abdelrahman M, Subzposh FA, Beer D, et al. Clinical Outcomes of His Bundle Pacing Compared to Right Ventricular Pacing. J Am Coll Cardiol. 2018;71(20):2319-30. doi:10.1016/j.jacc.2018.02.048.

516. Vijayaraman P, Naperkowski A, Ellenbogen KA, Dandamudi G. Electrophysiologic Insights Into Site of Atrioventricular Block: Lessons From Permanent His Bundle Pacing. JACC Clin Electrophysiol. 2015;1(6):571-81. doi:10.1016/j.jacep.2015.09.012.

517. St John Sutton M, Pfeffer MA, Plappert T, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation. 1994;89(1):68-75. doi:10.1161/01.cir.89.1.68.

518. Søholm H, Lønborg J, Andersen MJ, et al. Repeated echocardiography after first ever ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention--is it necessary? Eur Heart J Acute Cardiovasc Care. 2015;4(6):528-36. doi:10.1177/2048872614556000.

519. Daubert MA, White JA, Al-Khalidi HR, et al. Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era. Am Heart J. 2020;223:87-97. doi:10.1016/j.ahj.2020.02.017.

520. Chew DS, Heikki H, Schmidt G, et al. Change in Left Ventricular Ejection Fraction Following First Myocardial Infarction and Outcome. JACC Clin Electrophysiol. 2018;4(5):672-82. doi:10.1016/j.jacep.2017.12.015.

521. Moss AJ, Zareba W, Hall WJ, et al.; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-83. doi:10.1056/NEJMoa013474.

522. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292(23):2874-9. doi:10.1001/jama.292.23.2874.

523. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverterdefibrillators. N Engl J Med. 2005;353(14):1471-80. doi:10.1056/NEJMsa051989.

524. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341(25):1882-90. doi:10.1056/NEJM199912163412503. Erratum in: N Engl J Med 2000;342(17):1300.

525. Gatzoulis KA, Tsiachris D, Arsenos P, et al. Arrhythmic risk stratification in post-myocardial infarction patients with preserved ejection fraction: the PRESERVE EF study. Eur Heart J. 2019;40(35):2940-9. doi:10.1093/eurheartj/ehz260.

526. Hohnloser SH, Kuck KH, Dorian P, et al.; DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351(24):2481-8. doi:10.1056/NEJMoa041489.

527. Steinberg BA, Al-Khatib SM, Edwards R, et al. Outcomes of implantable cardioverterdefibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. JACC Heart Fail. 2014;2(6):623-9. doi:10.1016/j.jchf.2014.06.007.

528. Raphael CE, Finegold JA, Barron AJ, et al. The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most? Eur Heart J. 2015;36(26):1676-88. doi:10.1093/eurheartj/ehv102.

529. Miller RJ, Howlett JG, Exner DV, et al. Baseline Functional Class and Therapeutic Efficacy of Common Heart Failure Interventions: A Systematic Review and Meta-analysis. Can J Cardiol. 2015;31(6):792-9. doi:10.1016/j.cjca.2014.12.031.

530. Erkapic D, Sperzel J, Stiller S, et al., INSURE Investigators. Long-term benefit of implantable cardioverter/defibrillator therapy after elective device replacement: results of the INcidence free SUrvival after ICD REplacement (INSURE) trial — a prospective multicentre study. Eur Heart J. 2013;34(2):130-7. doi:10.1093/eurheartj/ehs177.

531. Kini V, Soufi MK, Deo R, et al. Appropriateness of primary prevention implantable cardioverter-defibrillators at the time of generator replacement: are indications still met? J Am Coll Cardiol. 2014;63(22):2388-94. doi:10.1016/j.jacc.2014.03.025.

532. Merchant FM, Jones P, Wehrenberg S, et al. Incidence of defibrillator shocks after elective generator exchange following uneventful first battery life. J Am Heart Assoc. 2014;3(6):e001289. doi:10.1161/JAHA.114.001289.

533. Yap SC, Schaer BA, Bhagwandien RE, et al. Evaluation of the need of elective implantable cardioverter-defibrillator generator replacement in primary prevention patients without prior appropriate ICD therapy. Heart. 2014;100(15):1188-92. doi:10.1136/heartjnl-2014-305535.

534. Alsheikh-Ali AA, Homer M, Maddukuri PV, et al. Time-dependence of appropriate implantable defibrillator therapy in patients with ischemic cardiomyopathy. J Cardiovasc Electrophysiol. 2008;19(8):784-9. doi:10.1111/j.1540-8167.2008.01111.x.

535. Ader F, De Groote P, Réant P, et al. FLNC pathogenic variants in patients with cardiomyopathies: Prevalence and genotype-phenotype correlations. Clin Genet. 2019;96(4):317-29. doi:10.1111/cge.13594.

536. Kayvanpour E, Sedaghat-Hamedani F, Amr A, et al. Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals. Clin Res Cardiol. 2017;106(2):127-39. doi:10.1007/s00392-016-1033-6.

537. Ortiz-Genga MF, Cuenca S, Dal Ferro M, et al. Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. J Am Coll Cardiol. 2016;68(22):2440-51. doi:10.1016/j.jacc.2016.09.927.

538. van den Hoogenhof MMG, Beqqali A, Amin AS, et al. RBM20 Mutations Induce an Arrhythmogenic Dilated Cardiomyopathy Related to Disturbed Calcium Handling. Circulation. 2018;138(13):1330-42. doi:10.1161/CIRCULATIONAHA.117.031947.

539. Gigli M, Merlo M, Graw SL, et al. Genetic Risk of Arrhythmic Phenotypes in Patients With Dilated Cardiomyopathy. J Am Coll Cardiol. 2019;74(11):1480-90. doi:10.1016/j.jacc.2019.06.072.

540. Wahbi K, Ben Yaou R, Gandjbakhch E, et al. Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. Circulation. 2019;140(4):293-302. doi:10.1161/CIRCULATIONAHA.118.039410.

541. van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol. 2012;59(5):493-500. doi:10.1016/j.jacc.2011.08.078.

542. Thuillot M, Maupain C, Gandjbakhch E, et al. External validation of risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers. Eur J Heart Fail. 2019;21(2):253-4. doi:10.1002/ejhf.1384.

543. León Salas B, Trujillo-Martín MM, García García J, et al. Subcutaneous implantable cardioverter-defibrillator in primary and secondary prevention of sudden cardiac death: A meta-analysis. Pacing Clin Electrophysiol. 2019;42(9):1253-68. doi:10.1111/pace.13774.

544. Сафиуллина А. А., Ускач Т. М., Сапельников О. В. и др. Эффективность модуляции сердечной сократимости у пациентов с хронической сердечной недостаточностью и фибрилляцией предсердий: результаты 12-месячного наблюдения. Терапевтический архив. 2022;94(9):1078-84. doi:10.26442/00403660.2022.09.201840.

545. Abraham WT, Kuck KH, Goldsmith RL, et al. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. JACC Heart Fail. 2018;6(10):874-83. doi:10.1016/j.jchf.2018.04.010. Erratum in: JACC Heart Fail. 2023;11(1):132. doi:10.1016/j.jchf.2022.11.003.

546. Kadish A, Nademanee K, Volosin K, et al. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J. 2011;161(2):329-37.e1-2. doi:10.1016/j.ahj.2010.10.025. Erratum in: Am Heart J. 2011;161(6):1220.

547. Borggrefe MM, Lawo T, Butter C, et al. Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J. 2008;29(8):1019-28. doi:10.1093/eurheartj/ehn020.

548. Wiegn P, Chan R, Jost C, et al. Safety, Performance, and Efficacy of Cardiac Contractility Modulation Delivered by the 2-Lead Optimizer Smart System: The FIX-HF-5C2 Study. Circ Heart Fail. 2020;13(4):e006512. doi:10.1161/CIRCHEARTFAILURE.119.006512.

549. Giallauria F, Cuomo G, Parlato A, et al. A comprehensive individual patient data meta-analysis of the effects of cardiac contractility modulation on functional capacity and heart failure-related quality of life. ESC Heart Fail. 2020;7(5):2922-32. doi:10.1002/ehf2.12902.

550. Frazier OH, Rose EA, Macmanus Q, et al. Multicenter clinical evaluation of the HeartMate 1000 IP left ventricular assist device. Ann Thorac Surg. 1992;53(6):1080-90. doi:10.1016/0003-4975(92)90393-i.

551. Garbade J, Gustafsson F, Shaw S, et al. Postmarket Experience With HeartMate 3 Left Ventricular Assist Device: 30-Day Outcomes From the ELEVATE Registry. Ann Thorac Surg. 2019;107(1):33-9. doi:10.1016/j.athoracsur.2018.07.092.

552. Jorde UP, Kushwaha SS, Tatooles AJ, et al.; HeartMate II Clinical Investigators. Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2014;63(17):1751-7. doi:10.1016/j.jacc.2014.01.053.

553. Kirklin JK, Naftel DC, Kormos RL, et al. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2014;33(1):12-22. doi:10.1016/j.healun.2013.11.001. Erratum in: J Heart Lung Transplant. 2015;34(10):1356.

554. Mehra MR, Salerno C, Cleveland JC, et al. Healthcare Resource Use and Cost Implications in the MOMENTUM 3 Long-Term Outcome Study. Circulation. 2018 Oct 30;138(18):1923-1934. doi:10.1161/CIRCULATIONAHA.118.035722.

555. Mehra MR, Uriel N, Naka Y, et al.; MOMENTUM 3 Investigators. A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report. N Engl J Med. 2019;380(17):1618-27. doi:10.1056/NEJMoa1900486.

556. Netuka I, Sood P, Pya Y, et al. Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF: A Multicenter Study. J Am Coll Cardiol. 2015;66(23):2579-89. doi:10.1016/j.jacc.2015.09.083.

557. Rose EA, Moskowitz AJ, Packer M, et al. The REMATCH trial: rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure. Ann Thorac Surg. 1999;67(3):723-30. doi:10.1016/s0003-4975(99)00042-9.

558. Schmitto JD, Hanke JS, Rojas SV, et al. First implantation in man of a new magnetically levitated left ventricular assist device (HeartMate III). J Heart Lung Transplant. 2015;34(6):858-60. doi:10.1016/j.healun.2015.03.001.

559. Starling RC, Estep JD, Horstmanshof DA, et al.; ROADMAP Study Investigators. Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: The ROADMAP Study 2-Year Results. JACC Heart Fail. 2017;5(7):518-27. doi:10.1016/j.jchf.2017.02.016.

560. Taylor RS, Walker S, Smart NA, et al.; ExTraMATCH II Collaboration. Impact of Exercise Rehabilitation on Exercise Capacity and Quality-of-Life in Heart Failure: Individual Participant Meta-Analysis. J Am Coll Cardiol. 2019;73(12):1430-43. doi:10.1016/j.jacc.2018.12.072.

561. Taylor RS, Walker S, Smart NA, et al.; ExTraMATCH II Collaboration. Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials. Eur J Heart Fail. 2018;20(12):1735-43. doi:10.1002/ejhf.1311.

562. Pandey A, Parashar A, Kumbhani D, et al. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail. 2015;8(1):33-40. doi:10.1161/CIRCHEARTFAILURE.114.001615.

563. Taylor RS, Long L, Mordi IR, et al. Exercise-Based Rehabilitation for Heart Failure: Cochrane Systematic Review, Meta-Analysis, and Trial Sequential Analysis. JACC Heart Fail. 2019;7(8):691-705. doi:10.1016/j.jchf.2019.04.023.

564. Taylor RS, Walker S, Ciani O, et al. Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis. Health Technol Assess. 2019;23(25):1-98. doi:10.3310/hta23250.

565. Kitzman DW, Brubaker PH, Herrington DM, et al. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. J Am Coll Cardiol. 2013;62(7):584-92. doi:10.1016/j.jacc.2013.04.033.

566. Ismail H, McFarlane J, Smart NA. Is exercise training beneficial for heart failure patients taking β-adrenergic blockers? A systematic review and meta-analysis. Congest Heart Fail. 2013;19(2):61-9. doi:10.1111/chf.12000.

567. Kitzman DW, Brubaker P, Morgan T, et al. Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA. 2016;315(1):36-46. doi:10.1001/jama.2015.17346.

568. Ambrosetti M, Abreu A, Corrà U, et al. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2021;28(5):460-95. doi:10.1177/2047487320913379.

569. Smart N, Marwick TH. Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity. Am J Med. 2004;116(10):693-706. doi:10.1016/j.amjmed.2003.11.033.

570. Buckley BJR, Harrison SL, Fazio-Eynullayeva E, Underhill P, Sankaranarayanan R, Wright DJ, Thijssen DHJ, Lip GYH. Cardiac rehabilitation and all-cause mortality in patients with heart failure: a retrospective cohort study. Eur J Prev Cardiol. 2021;28(15):1704-10. doi:10.1093/eurjpc/zwab035.

571. Stewart S, Vandenbroek AJ, Pearson S, Horowitz JD. Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. Arch Intern Med. 1999;159(3):257-61. doi:10.1001/archinte.159.3.257.

572. Anderson L, Sharp GA, Norton RJ, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev. 2017;6(6):CD007130. doi:10.1002/14651858.CD007130.pub4. Update in: Cochrane Database Syst Rev. 2023 Oct 27;10:CD007130. doi:10.1002/14651858.CD007130.pub5.

573. Chen YW, Wang CY, Lai YH, et al. Home-based cardiac rehabilitation improves quality of life, aerobic capacity, and readmission rates in patients with chronic heart failure. Medicine (Baltimore). 2018;97(4):e9629. doi:10.1097/MD.0000000000009629.

574. Lang CC, Smith K, Wingham J, et al.; REACH-HF investigators,. A randomised controlled trial of a facilitated home-based rehabilitation intervention in patients with heart failure with preserved ejection fraction and their caregivers: the REACH-HFpEF Pilot Study. BMJ Open. 2018;8(4):e019649. doi:10.1136/bmjopen-2017-019649. Erratum in: BMJ Open. 2019;9(3):e019649corr1. doi:10.1136/bmjopen-2017-019649corr1.

575. Zwisler AD, Norton RJ, Dean SG, et al. Home-based cardiac rehabilitation for people with heart failure: A systematic review and meta-analysis. Int J Cardiol. 2016;221:963-9. doi:10.1016/j.ijcard.2016.06.207.

576. Cavalheiro AH, Silva Cardoso J, Rocha A, et al. Effectiveness of Tele-rehabilitation Programs in Heart Failure: A Systematic Review and Meta-analysis. Health Serv Insights. 2021;14:11786329211021668. doi:10.1177/11786329211021668.

577. Dalal HM, Taylor RS, Jolly K, et al. The effects and costs of home-based rehabilitation for heart failure with reduced ejection fraction: The REACH-HF multicentre randomized controlled trial. Eur J Prev Cardiol. 2019;26(3):262-72. doi:10.1177/2047487318806358. Erratum in: Eur J Prev Cardiol. 2020;27(18):NP17. doi:10.1177/2047487320974256.

578. Thomas RJ, Beatty AL, Beckie TM, et al. Home-Based Cardiac Rehabilitation: A Scientific Statement From the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Heart Association, and the American College of Cardiology. Circulation. 2019;140(1):e69-e89. doi:10.1161/CIR.0000000000000663.

579. Piotrowicz E, Mierzyńska A, Banach M, et al. Quality of life in heart failure patients undergoing hybrid comprehensive telerehabilitation versus usual care — results of the Telerehabilitation in Heart Failure Patients (TELEREH-HF) Randomized Clinical Trial. Arch Med Sci. 2020;17(6):1599-612. doi:10.5114/aoms.2020.98350.

580. Lainscak M, Blue L, Clark AL, et al. Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;13(2):115-26. doi:10.1093/eurjhf/hfq219.

581. Schou M, Gustafsson F, Videbaek L, et al.; NorthStar Investigators, all members of The Danish Heart Failure Clinics Network. Extended heart failure clinic follow-up in low-risk patients: a randomized clinical trial (NorthStar). Eur Heart J. 2013;34(6):432-42. doi:10.1093/eurheartj/ehs235.

582. Gelbrich G, Störk S, Kreißl-Kemmer S, et al. Effects of structured heart failure disease management on mortality and morbidity depend on patients’ mood: results from the Interdisciplinary Network for Heart Failure Study. Eur J Heart Fail. 2014;16(10):1133-41. doi:10.1002/ejhf.150.

583. Kamiya K, Sato Y, Takahashi T, et al. Multidisciplinary Cardiac Rehabilitation and Long-Term Prognosis in Patients With Heart Failure. Circ Heart Fail. 2020;13(10):e006798. doi:10.1161/CIRCHEARTFAILURE.119.006798.

584. Jonkman NH, Westland H, Groenwold RH, et al. What Are Effective Program Characte ristics of Self-Management Interventions in Patients With Heart Failure? An Individual Patient Data Meta-analysis. J Card Fail. 2016;22(11):861-71. doi:10.1016/j.cardfail.2016.06.422.

585. Иванова Г. Е., Мельникова Е. В., Шмонин А. А. и др. Применение международной классификации функционирования в процессе медицинской реабилитации. Вестник восстановительной медицины. 2018;(6): 2-77.

586. Thomas RJ, Balady G, Banka G, et al. 2018 ACC/AHA Clinical Performance and Quality Measures for Cardiac Rehabilitation: A Report of the American College of Cardiology/ American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2018;71(16):1814-37. doi:10.1016/j.jacc.2018.01.004.

587. Piepoli MF, Corrà U, Adamopoulos S, et al. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy statement from the cardiac rehabilitation section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. Eur J Prev Cardiol. 2014;21(6):664-81. doi:10.1177/2047487312449597.

588. Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(10):1169-86. doi:10.1002/ejhf.1531.

589. Ambrosetti M, Abreu A, Cornelissen V, et al. Delphi consensus recommendations on how to provide cardiovascular rehabilitation in the COVID-19 era. Eur J Prev Cardiol. 2021;28(5):541-57. doi:10.1093/eurjpc/zwaa080.

590. Pogosova N, Saner H, Pedersen SS, et al.; Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. Psychosocial aspects in cardiac rehabilitation: From theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. Eur J Prev Cardiol. 2015t;22(10):1290-306. doi:10.1177/2047487314543075.

591. Sommaruga M, Angelino E, Della Porta P, et al. Best practice in psychological activities in cardiovascular prevention and rehabilitation: Position Paper. Monaldi Arch Chest Dis. 2018;88(2):966. doi:10.4081/monaldi.2018.966.

592. Agostoni P, Paolillo S, Mapelli M, et al. Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison. Eur J Heart Fail. 2018;20(4):700-10. doi:10.1002/ejhf.989.

593. Guazzi M, Adams V, Conraads V, et al.; European Association for Cardiovascular Prevention & Rehabilitation; American Heart Association. EACPR/AHA Scientific Statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation. 2012;126(18):2261-74. doi:10.1161/CIR.0b013e31826fb946.

594. Flynn KE, Piña IL, Whellan DJ, et al.; HF-ACTION Investigators. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301(14):1451-9. doi:10.1001/jama.2009.457. Erratum in: JAMA. 2009;302(21):2322.

595. Nolte K, Herrmann-Lingen C, Wachter R, et al. Effects of exercise training on different quality of life dimensions in heart failure with preserved ejection fraction: the Ex-DHF-P trial. Eur J Prev Cardiol. 2015;22(5):582-93. doi:10.1177/2047487314526071.

596. Cooper LB, Mentz RJ, Sun JL, et al. Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION). Circ Heart Fail. 2015;8(6):1044-51. doi:10.1161/CIRCHEARTFAILURE.115.002327. Erratum in: Circ Heart Fail. 2016;9(3):e000014. doi:10.1161/HHF.0000000000000014.

597. Ismail H, McFarlane JR, Nojoumian AH, et al. Clinical outcomes and cardiovascular responses to different exercise training intensities in patients with heart failure: a systematic review and meta-analysis. JACC Heart Fail. 2013;1(6):514-22. doi:10.1016/j.jchf.2013.08.006.

598. Long L, Mordi IR, Bridges C, et al. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev. 2019;1(1):CD003331. doi:10.1002/14651858.CD003331.pub5. Update in: Cochrane Database Syst Rev. 2024;3:CD003331. doi:10.1002/14651858.CD003331.pub6.

599. Bjarnason-Wehrens B, Nebel R, Jensen K, et al.; German Society of Cardiovascular Prevention and Rehabilitation (DGPR). Exercise-based cardiac rehabilitation in patients with reduced left ventricular ejection fraction: The Cardiac Rehabilitation Outcome Study in Heart Failure (CROS-HF): A systematic review and meta-analysis. Eur J Prev Cardiol. 2020;27(9):929-52. doi:10.1177/2047487319854140.

600. Working Group on Cardiac Rehabilitation & Exercice Physiology and Working Group on Heart Failure of the European Society of Cardiology. Recommendations for exercise training in chronic heart failure patients. Eur Heart J. 2001;22(2):125-35. doi:10.1053/euhj.2000.2440.

601. Cowie A, Thow MK, Granat MH, Mitchell SL. Effects of home versus hospital-based exercise training in chronic heart failure. Int J Cardiol. 2012;158(2):296-8. doi:10.1016/j.ijcard.2012.04.117.

602. Piotrowicz E, Baranowski R, Bilinska M, et al. A new model of home-based telemonitored cardiac rehabilitation in patients with heart failure: effectiveness, quality of life, and adherence. Eur J Heart Fail. 2010;12(2):164-71. doi:10.1093/eurjhf/hfp181.

603. Mezzani A, Hamm LF, Jones AM, et al.; European Association for Cardiovascular Prevention and Rehabilitation; American Association of Cardiovascular and Pulmonary Rehabilitation; Canadian Association of Cardiac Rehabilitation. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: a joint position statement of the European Association for Cardiovascular Prevention and Rehabilitation, the American Association of Cardiovascular and Pulmonary Rehabilitation and the Canadian Association of Cardiac Rehabilitation. Eur J Prev Cardiol. 2013;20(3):442-67. doi:10.1177/2047487312460484.

604. Gomes Neto M, Durães AR, Conceição LSR, et al. High intensity interval training versus moderate intensity continuous training on exercise capacity and quality of life in patients with heart failure with reduced ejection fraction: A systematic review and meta-analysis. Int J Cardiol. 2018;261:134-41. doi:10.1016/j.ijcard.2018.02.076.

605. Ellingsen Ø, Halle M, Conraads V, et al.; SMARTEX Heart Failure Study (Study of Myocardial Recovery After Exercise Training in Heart Failure) Group. High-Intensity Interval Training in Patients With Heart Failure With Reduced Ejection Fraction. Circulation. 2017;135(9):839-49. doi:10.1161/CIRCULATIONAHA.116.022924.

606. Haykowsky MJ, Timmons MP, Kruger C, et al. Meta-analysis of aerobic interval training on exercise capacity and systolic function in patients with heart failure and reduced ejection fractions. Am J Cardiol. 2013;111(10):1466-9. doi:10.1016/j.amjcard.2013.01.303.

607. van Halewijn G, Deckers J, Tay HY, et al. Lessons from contemporary trials of cardiovascular prevention and rehabilitation: A systematic review and meta-analysis. Int J Cardiol. 2017;232:294-303. doi:10.1016/j.ijcard.2016.12.125.

608. Jewiss D, Ostman C, Smart NA. The effect of resistance training on clinical outcomes in heart failure: A systematic review and meta-analysis. Int J Cardiol. 2016;221:674-81. doi:10.1016/j.ijcard.2016.07.046.

609. Giuliano C, Karahalios A, Neil C, et al. The effects of resistance training on muscle strength, quality of life and aerobic capacity in patients with chronic heart failure — A meta-analysis. Int J Cardiol. 2017;227:413-23. doi:10.1016/j.ijcard.2016.11.023.

610. Santos FV, Chiappa GR, Ramalho SHR, et al. Resistance exercise enhances oxygen uptake without worsening cardiac function in patients with systolic heart failure: a systematic review and meta-analysis. Heart Fail Rev. 2018;23(1):73-89. doi:10.1007/s10741-017-9658-8.

611. Laoutaris ID, Piotrowicz E, Kallistratos MS, et al.; ARISTOS-HF trial (Aerobic, Resistance, InSpiratory Training OutcomeS in Heart Failure) Investigators. Combined aerobic/ resistance/inspiratory muscle training as the ‘optimum’ exercise programme for patients with chronic heart failure: ARISTOS-HF randomized clinical trial. Eur J Prev Cardiol. 2021;28(15):1626-35. doi:10.1093/eurjpc/zwaa091.

612. Jesus IC, Menezes Junior FJ, Bento PCB, et al. Effect of combined interval training on the cardiorespiratory fitness in heart failure patients: a systematic review and meta-analysis. Braz J Phys Ther. 2020;24(1):8-19. doi:10.1016/j.bjpt.2019.04.001.

613. Adamopoulos S, Schmid JP, Dendale P, et al. Combined aerobic/inspiratory muscle training vs. aerobic training in patients with chronic heart failure: The Vent-HeFT trial: a European prospective multicentre randomized trial. Eur J Heart Fail. 2014;16(5):574-82. doi:10.1002/ejhf.70.

614. Wang MH, Yeh ML. Respiratory training interventions improve health status of heart failure patients: A systematic review and network meta-analysis of randomized controlled trials. World J Clin Cases. 2019;7(18):2760-75. doi:10.12998/wjcc.v7.i18.2760.

615. Lin SJ, McElfresh J, Hall B, et al. Inspiratory muscle training in patients with heart failure: a systematic review. Cardiopulm Phys Ther J. 2012;23(3):29-36.

616. Montemezzo D, Fregonezi GA, Pereira DA, et al. Influence of inspiratory muscle weakness on inspiratory muscle training responses in chronic heart failure patients: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2014;95(7):1398-407. doi:10.1016/j.apmr.2014.02.022.

617. Ploesteanu RL, Nechita AC, Turcu D, et al. Effects of neuromuscular electrical stimulation in patients with heart failure — review. J Med Life. 2018;11(2):107-18.

618. Gomes Neto M, Oliveira FA, Reis HF, et al. Effects of Neuromuscular Electrical Stimulation on Physiologic and Functional Measurements in Patients With Heart Failure: a systematic review with meta-analysis. J Cardiopulm Rehabil Prev. 2016;36(3):157-66. doi:10.1097/HCR.0000000000000151.

619. Feltner C, Jones CD, Cené CW, et al. Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis. Ann Intern Med. 2014;160(11):774-84. doi:10.7326/M14-0083.

620. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol. 2004;44(4):810-9. doi:10.1016/j.jacc.2004.05.055.

621. Phillips CO, Wright SM, Kern DE, et al. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA. 2004;291(11):1358-67. doi:10.1001/jama.291.11.1358. Erratum in: JAMA. 2004;292(9):1022.

622. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063. Erratum in: Circulation. 2022;145(18):e1033. doi:10.1161/CIR.0000000000001073. Erratum in: Circulation. 2022;146(13):e185. doi:10.1161/CIR.0000000000001097. Erratum in: Circulation. 2023;147(14):e674. doi:10.1161/CIR.0000000000001142.

623. McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi:10.1093/eurheartj/ehab368. Erratum in: Eur Heart J. 2021;42(48):4901. doi:10.1093/eurheartj/ehab670.

624. Beckett NS, Peters R, Fletcher AE, et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-98. doi:10.1056/NEJMoa0801369.

625. Sciarretta S, Palano F, Tocci G, et al. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med. 2011;171(5):384-94. doi:10.1001/archinternmed.2010.427.

626. SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-16. doi:10.1056/NEJMoa1511939. Erratum in: N Engl J Med. 2017;377(25):2506. doi:10.1056/NEJMx170008.

627. Scirica BM, Morrow DA, Cannon CP, et al.; PROVE IT-TIMI 22 Investigators. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2006;47(11):2326-31. doi:10.1016/j.jacc.2006.03.034. Erratum in: J Am Coll Cardiol. 2013;62(18):1727-9.

628. Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2016 Mar 17;374(11):1094. doi:10.1056/NEJMc1600827.

629. Neal B, Perkovic V, Mahaffey KW, et al.; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-57. doi:10.1056/NEJMoa1611925.

630. Wiviott SD, Raz I, Bonaca MP, et al.; DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-57. doi:10.1056/NEJMoa1812389.

631. Suskin N, Sheth T, Negassa A, Yusuf S. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;37(6):1677-82. doi:10.1016/s0735-1097(01)01195-0.

632. Gonçalves A, Claggett B, Jhund PS, et al. Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study. Eur Heart J. 2015;36(15):939-45. doi:10.1093/eurheartj/ehu514.

633. Pandey A, Garg S, Khunger M, et al. Dose-Response Relationship Between Physical Activity and Risk of Heart Failure: A Meta-Analysis. Circulation. 2015;132(19):1786-94. doi:10.1161/CIRCULATIONAHA.115.015853.

634. Padwal R, McAlister FA, McMurray JJ, et al.; Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. Int J Obes (Lond). 2014;38(8):1110-4. doi:10.1038/ijo.2013.203.

635. dams KF Jr, Fonarow GC, Emerman CL, et al.; ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149(2):209-16. doi:10.1016/j.ahj.2004.08.005.

636. Harjola VP, Lassus J, Sionis A, et al.; CardShock Study Investigators; GREAT network. Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail. 2015;17(5):501-9. doi:10.1002/ejhf.260. Erratum in: Eur J Heart Fail. 2015;17(9):984. doi:10.1002/ejhf.349.

637. Nieminen MS, Brutsaert D, Dickstein K, et al.; EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006;27(22):2725-36. doi:10.1093/eurheartj/ehl193.

638. Gheorghiade M, Abraham WT, Albert NM, et al.; OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296(18):2217-26. doi:10.1001/jama.296.18.2217.

639. Арутюнов А. Г., Рылова А. К., Арутюнов Г. П. Регистр госпитализированных пациентов с декомпенсацией кровообращения (павловский регистр). Сообщение 1. Современная клиническая характеристика пациента с декомпенсацией кровообращения. Клинические фенотипы пациентов. Журнал сердечная недостаточность. 2014;15(1):23-32.

640. Schiff GD, Fung S, Speroff T, McNutt RA. Decompensated heart failure: symptoms, patterns of onset, and contributing factors. Am J Med. 2003;114(8):625-30. doi:10.1016/s0002-9343(03)00132-3.

641. O’Connor CM, Stough WG, Gallup DS, et al. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail. 2005;11(3):200-5. doi:10.1016/j.cardfail.2004.08.160.

642. Valente MA, Voors AA, Damman K, et al. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J. 2014;35(19):1284-93. doi:10.1093/eurheartj/ehu065.

643. Виллевальде C. В., Соловьева А. Е., Звартау Н. Э. и др. Принципы организации медицинской помощи пациентам с сердечной недостаточностью в системе управления сердечно-сосудистыми рисками: фокус на преемственность и маршрутизацию пациентов. Практические материалы. Российский кардиологический журнал. 2021;26(3S):4558. doi:10.15829/1560-4071-2021-4558.

644. Shepperd S, Lannin NA, Clemson LM, et al. Discharge planning from hospital to home. Cochrane Database Syst Rev. 2013;(1):CD000313. doi:10.1002/14651858.CD000313.pub4. Update in: Cochrane Database Syst Rev. 2016;(1):CD000313. doi:10.1002/14651858.CD000313.pub5. Update in: Cochrane Database Syst Rev. 2022;2:CD000313. doi:10.1002/14651858.CD000313.pub6.

645. Bielecka-Dabrowa A, Godoy B, Schefold JC, et al. Decompensated Heart Failure and Renal Failure: What Is the Current Evidence? Curr Heart Fail Rep. 2018;15(4):224-38. doi:10.1007/s11897-018-0397-5.

646. Mebazaa A, Parissis J, Porcher R, et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Med. 2011;37(2):290-301. doi:10.1007/s00134-010-2073-4.

647. Фомин И. В., Краием Н., Поляков Д. С., и др. Понятие стабильности течения ХСН — приемлемо ли оно для российской практики? Кардиология. 2018;58(S3):55-63.

648. Stewart S. Financial aspects of heart failure programs of care. Eur J Heart Fail. 2005;7(3):423-8. doi:10.1016/j.ejheart.2005.01.001.

649. Shafie AA, Tan YP, Ng CH. Systematic review of economic burden of heart failure. Heart Fail Rev. 2018;23(1):131-45. doi:10.1007/s10741-017-9661-0.

650. McAlister FA, Lawson FM, Teo KK, Armstrong PW. A systematic review of randomized trials of disease management programs in heart failure. Am J Med. 2001;110(5):378-84. doi:10.1016/s0002-9343(00)00743-9.

651. Виноградова Н. Г., Поляков Д. С., Фомин И. В., Жиркова М. М. Прогноз жизни пациентов с хронической сердечной недостаточностью и фибрилляцией предсердий в зависимости от контроля гемодинамических показателей и толерантности к физической нагрузке на фоне базисной терапии. Кардиология. 2019;59(4S):51-8. doi:10.18087/cardio.2622.

652. Виноградова Н. Г. Городской центр лечения хронической сердечной недостаточности: организация работы и эффективность лечения пациентов с хронической сердечной недостаточностью. Кардиология. 019;59(2S):31-9.

653. Виноградова Н. Г., Жиркова М. М., Фомин И. В., Поляков Д. С. Эффективность лечения хронической сердечной недостаточности на амбулаторном этапе в условиях городского центра ХСН. Журнал сердечная недостаточность. 2017;18(4):270-8.

654. Фомин И. В., Виноградова Н. Г., Фарзалиев М. И., и др. Эффективность наблюдения пациентов в условиях специализированного центра лечения хронической сердечной недостаточности. Неотложная кардиология и кардиоваскулярные риски. 2018;2(1):221-9.

655. Inglis SC, Clark RA, McAlister FA, et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database Syst Rev. 2010;(8):CD007228. doi:10.1002/14651858.CD007228.pub2. Update in: Cochrane Database Syst Rev. 2015;(10):CD007228. doi:10.1002/14651858.CD007228.pub3.

656. Koehler F, Winkler S, Schieber M, et al.; TIM-HF Investigators. Telemedical Interventional Monitoring in Heart Failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study design. Eur J Heart Fail. 2010;12(12):1354-62. doi:10.1093/eurjhf/hfq199.

657. Jack BW, Chetty VK, Anthony D, et al. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med. 2009;150(3):178-87. doi:10.7326/0003-4819-150-3-200902030-00007.

658. Linden A, Butterworth S. A comprehensive hospital-based intervention to reduce readmissions for chronically ill patients: a randomized controlled trial. Am J Manag Care. 2014;20(10):783-92.

659. Wakefield BJ, Boren SA, Groves PS, Conn VS. Heart failure care management programs: a review of study interventions and meta-analysis of outcomes. J Cardiovasc Nurs. 2013;28(1):8-19. doi:10.1097/JCN.0b013e318239f9e1.

660. Van Spall HGC, Rahman T, Mytton O, Ramasundarahettige C, Ibrahim Q, Kabali C, Coppens M, Brian Haynes R, Connolly S. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis. Eur J Heart Fail. 2017;19(11):1427-43. doi:10.1002/ejhf.765.

661. Van Spall HGC, Lee SF, Xie F, et al. Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure: The PACT-HF Randomized Clinical Trial. JAMA. 2019;321(8):753-61. doi:10.1001/jama.2019.0710.

662. Sochalski J, Jaarsma T, Krumholz HM, et al. What works in chronic care management: the case of heart failure. Health Aff (Millwood). 2009;28(1):179-89. doi:10.1377/hlthaff.28.1.179.

663. Krumholz HM, Amatruda J, Smith GL, et al. Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. J Am Coll Cardiol. 2002;39(1):83-9. doi:10.1016/s0735-1097(01)01699-0.

664. Stewart S, Horowitz JD. Home-based intervention in congestive heart failure: long-term implications on readmission and survival. Circulation. 2002;105(24):2861-6. doi:10.1161/01.cir.0000019067.99013.67.

665. Фомин И. В., Виноградова Н. Г. Организация специализированной медицинской помощи больным с хроничекой сердечной недостаточностью. CardioСоматика. 2017;8(3):10-5.

666. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154(2):260-6. doi:10.1016/j.ahj.2007.01.041.

667. Maggioni AP, Dahlström U, Filippatos G, et al.; Heart Failure Association of the European Society of Cardiology (HFA). EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15(7):808-17. doi:10.1093/eurjhf/hft050.

668. Fonarow GC, Stough WG, Abraham WT, et al.; OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50(8):768-77. doi:10.1016/j.jacc.2007.04.064.

669. Alon D, Stein GY, Korenfeld R, Fuchs S. Predictors and outcomes of infection-related hospital admissions of heart failure patients. PLoS One. 2013;8(8):e72476. doi:10.1371/journal.pone.0072476.

670. Fonarow GC, Abraham WT, Albert NM, et al.; OPTIMIZE-HF Investigators and Hospitals. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med. 2008;168(8):847-54. doi:10.1001/archinte.168.8.847.

671. Sandoval C, Walter SD, Krueger P, et al. Risk of hospitalization during influenza season among , a cohort of patients with congestive heart failure. Epidemiol Infect. 2007;135(4):574-82. doi:10.1017/S095026880600714X.

672. Vardeny O, Claggett B, Udell JA, et al.; PARADIGM-HF Investigators. Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. JACC Heart Fail. 2016;4(2):152-8. doi:10.1016/j.jchf.2015.10.012.

673. Mohseni H, Kiran A, Khorshidi R, Rahimi K. Influenza vaccination and risk of hospitalization in patients with heart failure: a self-controlled case series study. Eur Heart J. 2017;38(5):326-33. doi:10.1093/eurheartj/ehw411.

674. Kopel E, Klempfner R, Goldenberg I. Influenza vaccine and survival in acute heart failure. Eur J Heart Fail. 2014;16(3):264-70. doi:10.1002/ejhf.14.

675. Modin D, Jørgensen ME, Gislason G, J et al. Influenza Vaccine in Heart Failure. Circulation. 2019;139(5):575-86. doi:10.1161/CIRCULATIONAHA.118.036788.

676. Marques Antunes M, Duarte GS, Brito D, et al. Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. 2021;7(1):97-106. doi:10.1093/ehjqcco/qcaa030.

677. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984;310(9):563-72. doi:10.1056/NEJM198403013100905.

678. Dzau VJ, Packer M, Lilly LS, et al. Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. N Engl J Med. 1984;310(6):347-52. doi:10.1056/NEJM198402093100603.

679. Van den Ouweland FA, Gribnau FW, Meyboom RH. Congestive heart failure due to nonsteroidal anti-inflammatory drugs in the elderly. Age Ageing. 1988;17(1):8-16. doi:10.1093/ageing/17.1.8.

680. Ungprasert P, Srivali N, Thongprayoon C. Nonsteroidal Anti-inflammatory Drugs and Risk of Incident Heart Failure: A Systematic Review and Meta-analysis of Observational Studies. Clin Cardiol. 2016;39(2):111-8. doi:10.1002/clc.22502.

681. Doukky R, Avery E, Mangla A, et al. Impact of Dietary Sodium Restriction on Heart Failure Outcomes. JACC Heart Fail. 2016;4(1):24-35. doi:10.1016/j.jchf.2015.08.007.

682. Paterna S, Gaspare P, Fasullo S, et al. Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? Clin Sci (Lond). 2008;114(3):221-30. doi:10.1042/CS20070193.

683. Stein C, Helal L, Migliavaca CB, et al. Are the recommendation of sodium and fluid restriction in heart failure patients changing over the past years? A systematic review and meta-analysis. Clin Nutr ESPEN. 2022;49:129-37. doi:10.1016/j.clnesp.2022.03.032.

684. Driggin E, Cohen LP, Gallagher D, et al. Nutrition Assessment and Dietary Interventions in Heart Failure: JACC Review Topic of the Week. J Am Coll Cardiol. 2022;79(16):1623-35. doi:10.1016/j.jacc.2022.02.025.

685. De Vecchis R, Paccone A, Di Maio M. Withdrawn: Effects of a restricted water intake on various clinical and laboratory outcomes in patients with heart failure: a meta-analysis of randomized controlled trials. Minerva Cardioangiol. 2020. doi:10.23736/S0026-4725.20.05072-0. Epub ahead of print.

686. Walsh CR, Larson MG, Evans JC, et al. Alcohol consumption and risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med. 2002;136(3):181-91. doi:10.7326/0003-4819-136-3-200202050-00005.

687. Crespo-Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(11):1505-35. doi:10.1002/ejhf.1236.

688. Brisco MA, Zile MR, Hanberg JS, et al. Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial. J Card Fail. 2016;22(10):753-60. doi:10.1016/j.cardfail.2016.06.423.

689. Bart BA, Goldsmith SR, Lee KL, et al.; Heart Failure Clinical Research Network. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367(24):2296-304. doi:10.1056/NEJMoa1210357.

690. Costanzo MR, Guglin ME, Saltzberg MT, et al.; UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49(6):675-83. doi:10.1016/j.jacc.2006.07.073.

691. Brännström M, Boman K. Effects of person-centred and integrated chronic heart failure and palliative home care. PREFER: a randomized controlled study. Eur J Heart Fail. 2014;16(10):1142-51. doi:10.1002/ejhf.151.

692. Lund LH, Carrero JJ, Farahmand B, et al. Association between enrolment in a heart failure quality registry and subsequent mortality-a nationwide cohort study. Eur J Heart Fail. 2017;19(9):1107-16. doi:10.1002/ejhf.762.

693. Comín-Colet J, Manito N, Segovia-Cubero J, et al.; LION-HEART Study Investigators. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail. 2018;20(7):1128-36. doi:10.1002/ejhf.1145.

694. Nizamic T, Murad MH, Allen LA, et al. Ambulatory Inotrope Infusions in Advanced Heart Failure: A Systematic Review and Meta-Analysis. JACC Heart Fail. 2018;6(9):757-67. doi:10.1016/j.jchf.2018.03.019.

695. Theochari CA, Michalopoulos G, Oikonomou EK, et al. Heart transplantation versus left ventricular assist devices as destination therapy or bridge to transplantation for 1-year mortality: a systematic review and meta-analysis. Ann Cardiothorac Surg. 2018;7(1):3-11. doi:10.21037/acs.2017.09.18.

696. Sahlollbey N, Lee CKS, Shirin A, Joseph P. The impact of palliative care on clinical and patient-centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials. Eur J Heart Fail. 2020;22(12):2340-2346. doi:10.1002/ejhf.1783.

697. Bjork JB, Alton KK, Georgiopoulou VV, et al. Defining Advanced Heart Failure: A Systematic Review of Criteria Used in Clinical Trials. J Card Fail. 2016;22(7):569-77. doi:10.1016/j.cardfail.2016.03.003.

698. Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41(10):1797-804. doi:10.1016/s0735-1097(03)00309-7.

699. Chakko S, Woska D, Martinez H, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med. 1991;90(3):353-9. doi:10.1016/0002-9343(91)80016-f.

700. Hummel YM, Liu LCY, Lam CSP, et al. Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. Eur J Heart Fail. 2017;19(12):1651-60. doi:10.1002/ejhf.957.

701. Quiñones MA, Greenberg BH, Kopelen HA, et al. Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 2000;35(5):1237-44. doi:10.1016/s0735-1097(00)00511-8.

702. Wong M, Staszewsky L, Latini R, et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. J Am Coll Cardiol. 2004;43(11):2022-7. doi:10.1016/j.jacc.2003.12.053.

703. Rossi A, Cicoira M, Bonapace S, et al. Left atrial volume provides independent and incremental information compared with exercise tolerance parameters in patients with heart failure and left ventricular systolic dysfunction. Heart. 2007;93(11):1420-5. doi:10.1136/hrt.2006.101261.

704. Paraskevaidis IA, Ikonomidis I, Simitsis P, et al. Multidimensional contractile reserve predicts adverse outcome in patients with severe systolic heart failure: a 4-year follow-up study. Eur J Heart Fail. 2017;19(7):846-61. doi:10.1002/ejhf.787.

705. Lichtenstein DA, Lascols N, Mezière G, Gepner A. Ultrasound diagnosis of alveolar consolidation in the critically ill. Intensive Care Med. 2004;30(2):276-81. doi:10.1007/s00134-003-2075-6.

706. Platz E, Lewis EF, Uno H, et al. Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patients. Eur Heart J. 2016;37(15):1244-51. doi:10.1093/eurheartj/ehv745.

707. Wang NC, Maggioni AP, Konstam MA, et al.; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA. 2008;299(22):2656-66. doi:10.1001/jama.299.22.2656.

708. Hawkins NM, Wang D, McMurray JJ, et al.; CHARM Investigators and Committees. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart. 2007;93(1):59-64. doi:10.1136/hrt.2005.083949.

709. Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015 Jun;17(6):544-58. doi:10.1002/ejhf.289.

710. Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47(10):1987-96. doi:10.1016/j.jacc.2005.11.084.

711. Ter Maaten JM, Damman K, Hanberg JS, et al. Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. Circ Heart Fail. 2016;9(8):e003109. doi:10.1161/CIRCHEARTFAILURE.116.003109.

712. Núñez J, Llàcer P, García-Blas S, et al. CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction. Am J Med. 2020 Mar;133(3):370-380.e4. doi:10.1016/j.amjmed.2019.07.041.

713. Nikolaou M, Parissis J, Yilmaz MB, et al. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J. 2013;34(10):742-9. doi:10.1093/eurheartj/ehs332.

714. Möckel M, de Boer RA, Slagman AC, et al. Improve Management of acute heart failure with ProcAlCiTonin in EUrope: results of the randomized clinical trial IMPACT EU Biomarkers in Cardiology (BIC) 18. Eur J Heart Fail. 2020;22(2):267-75. doi:10.1002/ejhf.1667.

715. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation. 2003;108(7):833-8. doi:10.1161/01.CIR.0000084543.79097.34.

716. Nellessen U, Goder S, Schobre R, et al. Serial analysis of troponin I levels in patients with ischemic and nonischemic dilated cardiomyopathy. Clin Cardiol. 2006;29(5):219-24. doi:10.1002/clc.4960290510.

717. Perna ER, Macin SM, Canella JP, et al. Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification. Circulation. 2004;110(16):2376-82. doi:10.1161/01.CIR.0000145158.33801.F3.

718. Fonarow GC, Peacock WF, Phillips CO, et al.; ADHERE Scientific Advisory Committee and Investigators. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol. 2007;49(19):1943-50. doi:10.1016/j.jacc.2007.02.037.

719. Januzzi JL Jr, Chen-Tournoux AA, Moe G. Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol. 2008;101(3A):29-38. doi:10.1016/j.amjcard.2007.11.017.

720. Pascual-Figal DA, Manzano-Fernández S, Boronat M, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail. 2011;13(7):718-25. doi:10.1093/eurjhf/hfr047.

721. Santaguida PL, Don-Wauchope AC, Ali U, et al. Incremental value of natriuretic peptide measurement in acute decompensated heart failure (ADHF): a systematic review. Heart Fail Rev. 2014;19(4):507-19. doi:10.1007/s10741-014-9444-9.

722. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27(3):330-7. doi:10.1093/eurheartj/ehi631.

723. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110(15):2168-74. doi:10.1161/01.CIR.0000144310.04433.BE.

724. Maisel A, Hollander JE, Guss D, et al.; Rapid Emergency Department Heart Failure Outpatient Trial investigators. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004;44(6):1328-33. doi:10.1016/j.jacc.2004.06.015.

725. Stienen S, Salah K, Eurlings LW, et al. Challenging the two concepts in determining the appropriate pre-discharge N-terminal pro-brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels? Eur J Heart Fail. 2015;17(9):936-44. doi:10.1002/ejhf.320.

726. Tomasoni D, Lombardi CM, Sbolli M, et al. Acute heart failure: More questions than answers. Prog Cardiovasc Dis. 2020 Sep-Oct;63(5):599-606. doi:10.1016/j.pcad.2020.04.007.

727. Park JH, Balmain S, Berry C, et al. Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction. Heart. 2010;96(7):533-8. doi:10.1136/hrt.2009.175257.

728. Vital FM, Ladeira MT, Atallah AN. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev. 2013;(5):CD005351. doi:10.1002/14651858.CD005351.pub3. Update in: Cochrane Database Syst Rev. 2019;4:CD005351. doi:10.1002/14651858.CD005351.pub4.

729. Weng CL, Zhao YT, Liu QH, et al. Meta-analysis: Noninvasive ventilation in acute cardiogenic pulmonary edema. Ann Intern Med. 2010;152(9):590-600. doi:10.7326/0003-4819-152-9-201005040-00009. Erratum in: Ann Intern Med. 2010;153(4):280. Erratum in: Ann Intern Med. 2010;153(1):67.

730. Gray AJ, Goodacre S, Newby DE, et al.; 3CPO Study Investigators. A multicentre randomised controlled trial of the use of continuous positive airway pressure and non-invasive positive pressure ventilation in the early treatment of patients presenting to the emergency department with severe acute cardiogenic pulmonary oedema: the 3CPO trial. Health Technol Assess. 2009;13(33):1-106. doi:10.3310/hta13330.

731. Masip J, Peacock WF, Price S, et al.; Acute Heart Failure Study Group of the Acute Cardiovascular Care Association and the Committee on Acute Heart Failure of the Heart Failure Association of the European Society of Cardiology. Indications and practical approach to non-invasive ventilation in acute heart failure. Eur Heart J. 2018;39(1):17-25. doi:10.1093/eurheartj/ehx580.

732. Harjola VP, Parissis J, Brunner-La Rocca HP, et al. Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2018;20(7):1081-99. doi:10.1002/ejhf.1204.

733. Wuerz RC, Meador SA. Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med. 1992;21(6):669-74. doi:10.1016/s0196-0644(05)82777-5.

734. Metra M, Felker GM, Zacà V, et al. Acute heart failure: multiple clinical profiles and mechanisms require tailored therapy. Int J Cardiol. 2010;144(2):175-9. doi:10.1016/j.ijcard.2010.04.003.

735. Felker GM, Lee KL, Bull DA, et al.; NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797-805. doi:10.1056/NEJMoa1005419.

736. Chioncel O, Mebazaa A, Harjola VP, et al.; ESC Heart Failure Long-Term Registry Investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(10):1242-54. doi:10.1002/ejhf.890.

737. Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(2):137-55. doi:10.1002/ejhf.1369.

738. Wakai A, McCabe A, Kidney R, et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev. 2013;2013(8):CD005151. doi:10.1002/14651858.CD005151.pub2.

739. Levy P, Compton S, Welch R, et al. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med. 2007;50(2):144-52. doi:10.1016/j.annemergmed.2007.02.022.

740. Kozhuharov N, Goudev A, Flores D, et al. Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure: The GALACTIC Randomized Clinical Trial. JAMA. 2019;322(23):2292-302. doi:10.1001/jama.2019.18598.

741. Freund Y, Cachanado M, Delannoy Q, et al. Effect of an Emergency Department Care Bundle on 30-Day Hospital Discharge and Survival Among Elderly Patients With Acute Heart Failure: The ELISABETH Randomized Clinical Trial. JAMA. 2020;324(19):1948-56. doi:10.1001/jama.2020.19378.

742. Simpson J, Castagno D, Doughty RN, et al.; Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC). Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis. Eur J Heart Fail. 2015;17(11):1182-91. doi:10.1002/ejhf.346.

743. Hou ZY, Chang MS, Chen CY, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J. 1995;16(4):521-8. doi:10.1093/oxfordjournals.eurheartj.a060945.

744. Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Haumer M, Gschwandtner M, Siostrzonek P, Heinz G. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med. 2001;29(6):1149-53. doi:10.1097/00003246-200106000-00011.

745. Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol. 1998;81(5):594-8. doi:10.1016/s0002-9149(97)00962-4.

746. Prins KW, Neill JM, Tyler JO, et al. Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis. JACC Heart Fail. 2015;3(8):647-53. doi:10.1016/j.jchf.2015.03.008. Erratum in: JACC Heart Fail. 2015;3(10):847.

747. Bhagat AA, Greene SJ, Vaduganathan M, et al. Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. JACC Heart Fail. 2019;7(1):1-12. doi:10.1016/j.jchf.2018.06.011.

748. Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400(10367):1938-52. doi:10.1016/S0140-6736(22)02076-1.

749. Komajda M, Cowie MR, Tavazzi L, et al.; QUALIFY Investigators. Physicians’ guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail. 2017;19(11):1414-23. doi:10.1002/ejhf.887.

750. Lund LH, Aaronson KD, Mancini DM. Predicting survival in ambulatory patients with severe heart failure on beta-blocker therapy. Am J Cardiol. 2003;92(11):1350-4. doi:10.1016/j.amjcard.2003.08.027.

751. Wachter R, Senni M, Belohlavek J, et al.; TRANSITION Investigators. Initiation of sacubitril/ valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019;21(8):998-1007. doi:10.1002/ejhf.1498.

752. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-74. doi:10.1038/s41591-021-01659-1.

753. Tromp J, Ponikowski P, Salsali A, et al. Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. Eur J Heart Fail. 2021;23(5):826-34. doi:10.1002/ejhf.2137.

754. Fonarow GC, Adams KF Jr, Abraham WT, et al.; ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293(5):572-80. doi:10.1001/jama.293.5.572.

755. Thorvaldsen T, Benson L, Ståhlberg M, et al. Triage of patients with moderate to severe heart failure: who should be referred to a heart failure center? J Am Coll Cardiol. 2014;63(7):661-71. doi:10.1016/j.jacc.2013.10.017.

756. Chioncel O, Ambrosy AP, Filipescu D, et al.; Romanian Acute Heart Failure Syndromes Study Investigators. Patterns of intensive care unit admissions in patients hospitalized for heart failure: insights from the RO-AHFS registry. J Cardiovasc Med (Hagerstown). 2015;16(5):331-40. doi:10.2459/JCM.0000000000000030.

757. Njoroge JN, Cheema B, Ambrosy AP, et al. Expanded algorithm for managing patients with acute decompensated heart failure. Heart Fail Rev. 2018;23(4):597-607. doi:10.1007/s10741-018-9697-9.

758. Huston JH, Ferre R, Pang PS, et al. Optimal Endpoints of Acute Heart Failure Therapy. Am J Ther. 2018;25(4):e465-e474. doi:10.1097/MJT.0000000000000792.

759. Chioncel O, Collins SP, Ambrosy AP, et al. Improving Postdischarge Outcomes in Acute Heart Failure. Am J Ther. 2018;25(4):e475-e486. doi:10.1097/MJT.0000000000000791.

760. Voors AA, Ouwerkerk W, Zannad F, et al. Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. Eur J Heart Fail. 2017;19(5):627-34. doi:10.1002/ejhf.785.

761. Chioncel O, Collins SP, Greene SJ, et al. Natriuretic peptide-guided management in heart failure. J Cardiovasc Med (Hagerstown). 2016;17(8):556-68. doi:10.2459/JCM.0000000000000329.

762. Breidthardt T, Weidmann ZM, Twerenbold R, et al. Impact of haemoconcentration during acute heart failure therapy on mortality and its relationship with worsening renal function. Eur J Heart Fail. 2017;19(2):226-36. doi:10.1002/ejhf.667.

763. Klein L. Treating Hemodynamic Congestion Is the Key to Prevent Heart Failure Hospitalizations. JACC Heart Fail. 2016;4(5):345-7. doi:10.1016/j.jchf.2016.03.004.

764. Bensimhon D, Alali SA, Curran L, et al. The use of the reds noninvasive lung fluid monitoring system to assess readiness for discharge in patients hospitalized with acute heart failure: A pilot study. Heart Lung. 2021;50(1):59-64. doi:10.1016/j.hrtlng.2020.07.003.

765. Lala A, Barghash MH, Giustino G, et al. Early use of remote dielectric sensing after hospitalization to reduce heart failure readmissions. ESC Heart Fail. 2021;8(2):1047-54. doi:10.1002/ehf2.13026.

766. Терещенко С. Н., Черемисина И. А., Сафиуллина А. А. Возможности улучшения терапии хронической сердечной недостаточности по результатам многоцентрового наблюдательного исследования BYHEART. Терапевтический архив. 2022;94(4):517-23. doi:10.26442/00403660.2022.04.201450.

767. Терещенко С. Н., Черемисина И. А., Сафиуллина А. А. Эффективность неотона у больных с хронической сердечной недостаточностью в зависимости от фракции выброса левого желудочка. Субанализ исследования BYHEART. Российский кардиологический журнал. 2022;27(11):5276. doi:10.15829/1560-4071-2022-5276.

768. Мазин П. В., Хафизьянова Р. Ф., Мазин В. П., Краснова В. В. Мета-анализ эффективности адъювантного применения фосфокреатина при лечении хронической сердечной недостаточности. Вятский медицинский вестник. 2022;(4):92-9. doi:10.24412/2220-7880-2022-4-92-99. EDN: QYOGDG

769. Jing Z. Efficacy of sacubitril valsartan combined with sodium creatine phosphate in the treatment of chronic heart failure. Chinese Journal of Practical Medicine. Sep. 2020;47(18). doi:10.3760/cma.j.cn115689-20200604-02804.

770. Михин В. П., Николенко Т. А., Громнацкий Н. И. Эффективность креатинфосфата в составе комплексной терапии у больных с хронической сердечной недостаточностью, перенесших инфаркт миокарда с подъемом сегмента ST. Лечебное дело. 2020;(1):64-70. doi:10.24411/2071-5315-2020-12194.

771. Grazioli I, Melzi G, Strumia E. Multicenter controlled study of creatine phosphate in the treatment of heart failure. Curr Therap Res. 1992;52:271-80.

772. Peng W. Clinical effect of sodium creatine phosphate in the treatment of chronic heart failure. Chinese Medicine. 2013;8(9). doi:10.3760/cma.j.issn.1673-4777.013.09.004.

773. Li XH, Xing YQ, Zhang X, et al. Clinical efficacy of exogenous phosphocreatine in the treatment of elderly patients with chronic heart failure and its impact on heart failure markers. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease. 2020;28(6):42-6.

774. Симаков А. А., Поляева Л. В., Рязанова Е. И. Пути оптимизации лечения больных хронической сердечной недостаточностью на фоне ишемической болезни сердца. Кардиология и сердечно-сосудистая хирургия. 2014;7(5):20-3.

775. Jonkman NH, Westland H, Groenwold RH, et al. Do Self-Management Interventions Work in Patients With Heart Failure? An Individual Patient Data Meta-Analysis. Circulation. 2016;133(12):1189-98. doi:10.1161/CIRCULATIONAHA.115.018006.

776. Gayat E, Arrigo M, Littnerova S, et al.; GREAT Network. Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study. Eur J Heart Fail. 2018;20(2):345-54. doi:10.1002/ejhf.932.

777. Lee KK, Yang J, Hernandez AF, et al. Post-discharge Follow-up Characteristics Associated With 30-Day Readmission After Heart Failure Hospitalization. Med Care. 2016;54(4):365-72. doi:10.1097/MLR.0000000000000492.

778. Edmonston DL, Wu J, Matsouaka RA, et al. Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patients. Am Heart J. 2019;212:101-12. doi:10.1016/j.ahj.2019.03.005.

779. Ouwerkerk W, Voors AA, Anker SD, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017;38(24):1883-90. doi:10.1093/eurheartj/ehx026.

780. Iakobishvili Z, Cohen E, Garty M, et al.; Heart Failure Survey in Isarel (HFSIS) Investigators. Use of intravenous morphine for acute decompensated heart failure in patients with and without acute coronary syndromes. Acute Card Care. 2011;13(2):76-80. doi:10.3109/17482941.2011.575165.

781. Peacock WF, Hollander JE, Diercks DB, et al. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J. 2008;25(4):205-9. doi:10.1136/emj.2007.050419.

782. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287(12):1531-40. doi:10.1001/jama.287.12.1531. Erratum in: JAMA 2002;288(5):577.

783. Khot UN, Novaro GM, Popović ZB, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med. 2003;348(18):1756-63. doi:10.1056/NEJMoa022021.

784. Cox ZL, Hung R, Lenihan DJ, Testani JM. Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial. JACC Heart Fail. 2020;8(3):157-68. doi:10.1016/j.jchf.2019.09.012.

785. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010;56(19):1527-34. doi:10.1016/j.jacc.2010.06.034.

786. Mullens W, Dauw J, Martens P, et al.; ADVOR Study Group. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med. 2022;387(13):1185-95. doi:10.1056/NEJMoa2203094.

787. Maack C, Eschenhagen T, Hamdani N, et al. Treatments targeting inotropy. Eur Heart J. 2019;40(44):3626-44. doi:10.1093/eurheartj/ehy600.

788. Mebazaa A, Nieminen MS, Filippatos GS, et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail. 2009;11(3):304-11. doi:10.1093/eurjhf/hfn045.

789. O’Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999;138(1 Pt 1):78-86. doi:10.1016/s0002-8703(99)70250-4.

790. Belletti A, Castro ML, Silvetti S, et al. The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials. Br J Anaesth. 2015;115(5):656-75. doi:10.1093/bja/aev284.

791. Mebazaa A, Motiejunaite J, Gayat E, et al.; ESC Heart Failure Long-Term Registry Investigators. Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry. Eur J Heart Fail. 2018;20(2):332-41. doi:10.1002/ejhf.991.

792. Packer M, Colucci W, Fisher L, et al.; REVIVE Heart Failure Study Group. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1(2):103-11. doi:10.1016/j.jchf.2012.12.004.

793. De Backer D, Biston P, Devriendt J, et al.; SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779-89. doi:10.1056/NEJMoa0907118.

794. Levy B, Clere-Jehl R, Legras A, et al.; Collaborators. Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction. J Am Coll Cardiol. 2018;72(2):173-82. doi:10.1016/j.jacc.2018.04.051.

795. Léopold V, Gayat E, Pirracchio R, et al. Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. Intensive Care Med. 2018;44(6):847-56. doi:10.1007/s00134-018-5222-9. Erratum in: Intensive Care Med. 2018;44(11):2022-3. doi:10.1007/s00134-018-5372-9.

796. Russell JA. Vasopressor therapy in critically ill patients with shock. Intensive Care Med. 2019;45(11):1503-17. doi:10.1007/s00134-019-05801-z.

797. Perman SM, Elmer J, Maciel CB, et al.; American Heart Association. 2023 American Heart Association Focused Update on Adult Advanced Cardiovascular Life Support: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2024;149(5):e254-e273. doi:10.1161/CIR.0000000000001194.

798. Khand AU, Rankin AC, Martin W, et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol. 2003;42(11):1944-51. doi:10.1016/j.jacc.2003.07.020.

799. Dentali F, Douketis JD, Gianni M, et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med. 2007;146(4):278-88. doi:10.7326/0003-4819-146-4-200702200-00007.

800. Sintek MA, Gdowski M, Lindman BR, et al. Intra-Aortic Balloon Counterpulsation in Patients With Chronic Heart Failure and Cardiogenic Shock: Clinical Response and Predictors of Stabilization. J Card Fail. 2015;21(11):868-76. doi:10.1016/j.cardfail.2015.06.383.

801. Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52(19):1584-8. doi:10.1016/j.jacc.2008.05.065.

802. Ouweneel DM, Eriksen E, Sjauw KD, et al. Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction. J Am Coll Cardiol. 2017;69(3):278-87. doi:10.1016/j.jacc.2016.10.022.

803. Dhruva SS, Ross JS, Mortazavi BJ, et al. Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. JAMA. 2020;323(8):734-45. doi:10.1001/jama.2020.0254.

804. Schrage B, Ibrahim K, Loehn T, et al. Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock. Circulation. 2019;139(10):1249-58. doi:10.1161/CIRCULATIONAHA.118.036614.

805. Kar B, Gregoric ID, Basra SS, et al. The percutaneous ventricular assist device in severe refractory cardiogenic shock. J Am Coll Cardiol. 2011;57(6):688-96. doi:10.1016/j.jacc.2010.08.613.

806. Ouweneel DM, Schotborgh JV, Limpens J, et al. Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. Intensive Care Med. 2016;42(12):1922-34. doi:10.1007/s00134-016-4536-8.

807. Combes A, Price S, Slutsky AS, Brodie D. Temporary circulatory support for cardiogenic shock. Lancet. 2020;396(10245):199-212. doi:10.1016/S0140-6736(20)31047-3.

808. Pappalardo F, Schulte C, Pieri M, et al. Concomitant implantation of Impella® on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail. 2017;19(3):404-12. doi:10.1002/ejhf.668.

809. Anderson MB, Goldstein J, Milano C, et al. Benefits of a novel percutaneous ventricular assist device for right heart failure: The prospective RECOVER RIGHT study of the Impella RP device. J Heart Lung Transplant. 2015;34(12):1549-60. doi:10.1016/j.healun.2015.08.018.

810. Thiele H, Zeymer U, Neumann FJ, et al.; Intraaortic Balloon Pump in cardiogenic shock II (IABP-SHOCK II) trial investigators. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet. 2013;382(9905):1638-45. doi:10.1016/S0140-6736(13)61783-3.

811. Thiele H, Zeymer U, Thelemann N, et al.; IABP-SHOCK II Trial (Intraaortic Balloon Pump in Cardiogenic Shock II) Investigators; IABP-SHOCK II Investigators. Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction: Long-Term 6-Year Outcome of the Randomized IABP-SHOCK II Trial. Circulation. 2019;139(3):395-403. doi:10.1161/CIRCULATIONAHA.118.038201.

812. Беленков Ю. Н., Мареев В. Ю. Принципы рационального лечения хронической сердечной недостаточности. М.: Медиа Медика. 2000. 266 с.

813. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132(8):919-23.

814. Faggiano P, D’Aloia A, Gualeni A, et al. The 6 minute walking test in chronic heart failure: indications, interpretation and limitations from a review of the literature. Eur J Heart Fail. 2004;6(6):687-91. doi:10.1016/j.ejheart.2003.11.024.

815. Zielińska D, Bellwon J, Rynkiewicz A, Elkady MA. Prognostic value of the six-minute walk test in heart failure patients undergoing cardiac surgery: a literature review. Rehabil Res Pract. 2013;2013:965494. doi:10.1155/2013/965494.

816. Ingle L, Cleland JG, Clark AL. The long-term prognostic significance of 6-minute walk test distance in patients with chronic heart failure. Biomed Res Int. 2014;2014:505969. doi:10.1155/2014/505969.

817. Ingle L, Cleland JG, Clark AL. The relation between repeated 6-minute walk test performance and outcome in patients with chronic heart failure. Ann Phys Rehabil Med. 2014;57(4):244-53. doi:10.1016/j.rehab.2014.03.004.

818. Pollentier B, Irons SL, Benedetto CM, et al. Examination of the six minute walk test to determine functional capacity in people with chronic heart failure: a systematic review. Cardiopulm Phys Ther J. 2010;21(1):13-21.

819. Palau P, Domínguez E, Núñez E, et al. Six-minute walk test in moderate to severe heart failure with preserved ejection fraction: Useful for functional capacity assessment? Int J Cardiol. 2016;203:800-2. doi:10.1016/j.ijcard.2015.11.074.

820. Forman DE, Fleg JL, Kitzman DW, et al. 6-min walk test provides prognostic utility comparable to cardiopulmonary exercise testing in ambulatory outpatients with systolic heart failure. J Am Coll Cardiol. 2012;60(25):2653-61. doi:10.1016/j.jacc.2012.08.1010.

821. Kaminsky LA, Tuttle MS. Functional assessment of heart failure patients. Heart Fail Clin. 2015;11(1):29-36. doi:10.1016/j.hfc.2014.08.002.

Документы

Источник

Информация

Автор

Название журнала

Российский кардиологический журнал

Ключевые слова

Статья